1970

**American Association of Cancer Institutes (AACI), 1970**

Office of the President

Follow this and additional works at: [https://openworks.mdanderson.org/op_bertnerclark](https://openworks.mdanderson.org/op_bertnerclark)
Minutes

Association of American Cancer Institutes

M. D. Anderson Hospital and Tumor Institute,
Houston, Texas

May 25, 1970

Dr. Nicky opened the meeting at the M. D. Anderson Library and
Dr. Clark welcomed the many foreign institute directors or their repre-
sentatives. Dr. Clark stressed the purpose of the organization and its
usefulness.

Dr. Horsfall presided as President of the Association of American
Cancer Institutes and again re-stated how beneficial the AACI was to the
cancer institute directors.

Dr. Horsfall asked that the minutes of the Buffalo meeting of the
Association held November 2-3, 1959, be accepted and they were so accepted.

Dr. Horsfall then called upon Dr. Mirand to review, for the benefit of
the foreign guests, the number of institutes which are members of the
Association of American Cancer Institutes. Dr. Mirand advised there were
22 American cancer institutes participating in the AACI. Dr. Mirand also
reported that 93 foreign institute directors were contacted and invited to
meet with the AACI at the M. D. Anderson Hospital and Tumor Institute at
the time of the Xth International Cancer Congress. He reviewed the responses
as follows: 41 said yes, they would attend; 21 said no; and no response was
received from 31.

Dr. Mirand noted that he had received resignations from the Association
of American Cancer Institutes from Dr. Alfred Gellhorn, Dean of the School
of Medicine at the University of Pennsylvania; Dr. Leonard P. Eliel of the
Oklahoma Medical Research Foundation who is now the Director of the University of Oklahoma Medical Center's Graduate and Research Affairs; Dr. A. R. Curreri, Director of the Division of Clinical Oncology, University of Wisconsin Medical Center, Madison; and Mr. Russell E. Merritt from the Cancer Research Center, Columbia, Missouri.

Dr. Paul T. Condit, Head of the Cancer Section, Oklahoma Medical Research Foundation, will replace Dr. Eliel as their representative while Dr. Robert O. Johnson, Director of the Division of Clinical Oncology, will replace Dr. Curreri as the member of the Association representing the University of Wisconsin Medical Center. Dr. Curreri will continue to serve as an alternate. Dr. Harry D. Brown will serve as an alternate for the Cancer Research Center, Columbia, Missouri.

Dr. Mirand reported that 20 of the 22 cancer institutes had donated or committed to donate $100 for the social-scientific affair honoring the foreign institute directors and representatives. He stated 15 institutes had paid, 5 promised to pay, and 2 institutes were unable to contribute. At the time of the meeting, the Treasury of AACI contained $1500 and this appeared to be ample to cover the expenses of the meeting.

Dr. Mirand then called for Dr. Owens to go over the plans for the fall meeting of the Association but Dr. Owens was not in attendance. Therefore, the date for the fall meeting could not be finalized but the meeting will be held at Johns Hopkins in Baltimore, perhaps October 18-20, 1970.

Several of the foreign institute directors made comments during the meeting. For instance, Prof. N. N. Blokhin from the USSR stressed that at the next meeting of the IUCC we should arrange a formal session for all cancer institute directors in the world. He said that the USSR had 22 cancer institutes.
Dr. Ercole Sega from Italy thanked the Association for inviting him and hoped that the IUCC meeting could be in Florence. He asked what our association was with the American Association for Cancer Research. At that time, Dr. Baker requested Dr. Horsfall to explain, in addition, the American Cancer Society and the AMCR since there might be some confusion there, too, for the foreign guests. Dr. Horsfall related that we had no formal association with the American Cancer Society or the American Association for Cancer Research.

Dr. M. Gaitan Yanguas from Bogota, Colombia, wanted to know if we had any association with the American Hospital Association and Dr. Horsfall said we did not.

Dr. Talbot proceeded to say that the Association of American Cancer Institutes is a very informal group and we don't even collect dues.

Dr. John Higginson from Lyon, France, stated that he plans to have the cancer institute directors meet in Lyon, France, to discuss mutual problems and stressed that this would be of great value.

Dr. Hickey stressed that we all should see the typical hospital room at the Exhibit.

Dr. Horsfall, in closing the meeting, thanked the foreign guests for attending the meeting and hoped that we could arrange in the future some interchange between the Association of American Cancer Institutes and their respective institutes.

Dr. Horsfall then invited all the foreign and U. S. A. cancer institute directors or their representatives to a reception and buffet-dinner at the Anderson-Mayfair Hotel. This proved to be a very successful affair.
The expenses for the reception and buffet-dinner were paid by fees collected from the various Institute members of the AACI. The expenses totaled $827.40. Dr. Mirand paid these bills for the Association at the request of Dr. Hickey who submitted final receipts. Appropriate checks were made out to the M. D. Anderson Hospital for a total of $147.40 to cover postage, photographs and mailers, and the printing of invitations. A check in the amount of $680.00 was also made payable to the Anderson-Mayfair Hotel to cover the expenses for the reception and buffet-dinner.

E. A. Mirand
Secretary-Treasurer, AACI
DEVELOPMENT OF MULTIDISCIPLINARY RESEARCH CENTERS IN ACADEMIC INSTITUTIONS

Alfred Gellhorn, Chairman (Columbia University)
Carl G. Baker (National Cancer Institute)
William B. Bean (University of Iowa)
R. Lee Clark (M.D. Anderson Hospital and Tumor Institute)
Sidney Farber (Children's Cancer Research Foundation)
William U. Gardner (Yale University)
Alfred Gilman (Albert Einstein College of Medicine)
Erich Hirschberg (recorder) (Columbia University)
William N. Hubbard, Jr. (University of Michigan)
Paul Kotin (USPHS--Division of Environmental Health Sciences)
Johannes Rhodin (New York Medical College)
Herold P. Rusch (University of Wisconsin)
DeWitt Stetten, Jr. (Rutgers Medical School)
Paul C. Zamecnik (Massachusetts General Hospital)

Jesse Steinfeld, Univ. of So. Calif., was unable to attend

In addition, the following guests participated: Abraham Cantarow, Kenneth M. Endicott, Robert E. Greenfield, Michael Klein, Palmer Saunders, Miss Pauline Stephan (all from the National Cancer Institute), and G. Congdon Wood (American Cancer Society).
INTRODUCTION

In his introductory comments, Dr. Gellhorn reviewed the purposes of this ad hoc committee, one of the ten panels organized by the National Advisory Cancer Council to consider the present status and future objectives of research in chemical carcinogenesis and to formulate recommendations for action on a national scale. It was pointed out that most of the other panels were concerned primarily with the identification of gaps in current scientific knowledge in this research area and with the development of specific programs for further investigative efforts, whereas the present discussion group was organized to consider administrative techniques and organizational structures which would be most useful in the implementation of the multidisciplinary and mission-oriented programs now being envisaged. It was proposed that the agenda for the day's discussion include the advantages and disadvantages of conducting such programs in medical schools and universities, the relationship of this type of research to undergraduate and postgraduate training, the problems posed by clinical research in contrast to laboratory studies, and the variety of administrative mechanisms utilized here and abroad to these ends.

The first part of the meeting was devoted to the exposition of the individual views of the committee members, highlighting in turn the possible methods of implementation of multidisciplinary programs in chemical carcinogenesis being considered by the United States Public Health Service, the established mechanisms in several existing cancer research institutes, the views of persons responsible for the overall functions of a medical school, and the dimensions of the problem as seen by representatives of scientific disciplines. This was followed by extensive general discussion and the eventual emergence of a consensus on specific recommendations from this panel to the National Advisory Cancer Council.
EXPOSITION OF INDIVIDUAL VIEWS

Dr. Baker outlined the dimensions of the problem of carcinogenesis and illustrated the multidisciplinary nature of the effort needed for its solution. The intimate interrelationships between biometry, epidemiology, mathematics, statistics, chemistry, several areas of biology, pharmacology, toxicology, and engineering in mounting such an attack were stressed, as was the need for further development of techniques and collection of information within each of these disciplines. A spectrum of organizational arrangements, ranging from a single major center with program responsibility for the total effort, through independent corporations or university centers, to departmental or interdepartmental groups within universities or medical schools, was discussed. Some consideration was given to the problem of critical size for effective operation, to possible mechanisms for integration of the efforts and results in various centers physically separated from each other, and to the challenge inherent in the translation of research findings into preventive action on a broad scale. It was stated that total or partial funding by the National Cancer Institute could take a variety of forms and that flexibility of eventual organizational arrangements was of prime importance.

Dr. Kotin discussed the implementation of this sort of multidisciplinary program, drawing on the current experience of the Division of Environmental Health Sciences and illustrating in detail the interdependence and cross-fertilization of the demographic and experimental approaches. He enumerated the multiple environmental and host factors involved and pointed out that demographic studies have sufficed to initiate preventive measures with respect to occupational groups exposed to high risk of lung, skin, and bladder cancer and with regard to the general population and its risk of lung cancer, but that these studies have not yet sufficed to initiate preventive measures with respect to breast cancer in the United States, esophageal cancer in Latin America, liver cancer in Africa, and stomach cancer in Japan. He traced the contributions of related laboratory studies, particularly with regard to the possible hepatocarcinogenic activity of aflatoxin and the risks inherent in exposure to the pesticide, acetylaminofluorene, and the commercial solvent, dimethylnitrosamine. It was emphasized that these interrelated approaches to the problem of chemical carcinogenesis could suitably be pursued within the university environment.

Dr. Farber traced briefly the rapid expansion of research within medical schools in the last few decades and questioned the adequacy of traditional organizational patterns to meet this challenge. The continuing essential role of academic departments in the perpetuation of the various scientific disciplines and the training of the next generation of researchers was emphasized and the high quality and pertinence of much of the work done within the present framework were organized, but it was stressed that the emerging need for broad multidisciplinary programs in cancer called for the creation of additional and differently organized research entities.
It was pointed out that at this time, with very few exceptions, cancer research institutes of any magnitude are not integrated closely into established medical schools in an intellectual or organizational sense, that a continuing feeling of hopelessness with regard to neoplastic disease tends to pervade the medical school environment, and that competition for space and funds between categorical and general research and between investigative and educational programs must be recognized as another widespread problem. It was considered essential to create cancer research centers within medical schools without relegating these centers to second-class status or impeding their freedom to draw on the broad resources of the institution for the required multidisciplinary attack on the problem, but at the same time without damaging the medical school program in education and in perpetuation of the various fundamental disciplines. To this end, the creation of horizontal Divisions of Oncology, cutting across and interacting with the diverse vertical Departments of academic institutions, was envisaged. These Divisions, to attract and keep appropriate staff, must have the power of appointment, either jointly with a Department for investigators interested in also continuing participation in teaching and research in their own discipline or solely within the Division for persons wishing to devote all their efforts to mission-oriented research or those not easily categorized within a single discipline. The feasibility and advantages of this sort of flexible arrangement from the points of view of both the parent institutions and the categorical research centers were discussed.

Dr. Clark, drawing on the experience of witnessing the growth of the M.D. Anderson Hospital and Tumor Institute within the University of Texas during the past two decades, proposed to emphasize the positive steps needed rather than the negative obstacles in setting up cancer centers. The advantages inherent in the association with a university, particularly with regard to the stimulation by the academic environment and the ease of recruitment of personnel, were outlined. It was felt that in view of the additional special problems which medical schools face in financing, it was preferable to have categorical research centers integrated into the graduate rather than the medical faculty. With regard to inter-departmental relations, it was deemed best to set up task forces for specific missions which would draw on researchers who maintained their roots in their own discipline. The size of any particular task force or center was considered of little import, but the essentiality of fiscal and organizational autonomy was stressed. Regret was expressed that clinicians interested in cancer currently face the additional handicap that training in oncology is usually not acceptable for specialty certification in medicine, surgery, radiology, and so on, and the hope was voiced that this situation might soon be corrected.
Dr. Rusch reviewed the three current types of organization devoted to cancer research, i.e., the multidisciplinary cancer institute associated with a university, the cancer center within a university drawing on individual department members, and the formal department of oncology in an academic institution. The history and structure of the McArdle Laboratory for Cancer Research at the University of Wisconsin -- the only current example of the third type of organization -- were discussed in detail to indicate one way in which a viable mechanism for categorical research can be maintained. Among the positive features cited were the maintenance of manageable size of this research group (currently 13 faculty members, 26 graduate students, and 35 postdoctoral fellows), its continued concentration on biochemical and molecular-biological approaches to the cancer problem, its close cooperation with the other groups in the University engaged in cancer research (clinical oncology, radiobiology and radiotherapy), its ability to initiate appointments and propose promotions directly to the appropriate university officials, its parity with other departments with regard to salary levels, and the participation of its staff in teaching at the graduate and medical school levels.

Dr. Gardner addressed himself to the relationships of a categorical interdisciplinary institute for research in carcinogenesis to educational and teaching responsibilities of a university medical school, particularly with regard to the training of medical students, graduate students, and postdoctoral fellows. The experience at Yale with several interdisciplinary centers was reviewed briefly, but it was emphasized that there have been and continue to be such explosive changes in the ecology of the contemporary medical science researcher that experiences of earlier times are not of major significance in planning future policy. These changes relate to reorganization of the curriculum and of academic departments, pronounced shortening of the half-life of pertinent knowledge and useful techniques, increased emphasis on specialization rather than general medical education, greatly augmented support for and scope of health science research, and more widespread acceptance of interdisciplinary collaboration. In many ways, these changes may be expected to favor the establishment and integration of categorical research centers within university medical schools, with evident benefit to both. To be most viable and contributory in this setting, a categorical institute should concentrate on those aspects of carcinogenesis which are approached at the fundamental research level rather than from the point of view of development and application; it should assume a continuing responsibility for training and teaching at medical and graduate school levels; it should have discrete geographic localization and administrative autonomy without sacrificing close interrelations with the remainder of the institution; it should not exceed a manageable critical size; it should provide support and tenure comparable to that of other members of the staff; and it should preserve flexibility in terms of objectives and organization.

Dr. Hubbard indicated that investigations can be and are undertaken at a very high level entirely divorced from a university setting, but that
there are real advantages in terms of recruitment, special equipment, and academic atmosphere when mission-oriented research is conducted within this setting. It was emphasized that a categorical research center would be entirely parasitic on a university, and therefore not likely to be acceptable to deans and other officers of the latter, unless the new effort was clearly incremental, non-competitive, and autonomous. It must not drain existing facilities or funds or manpower but stand ready to contribute to the functions of the parent institution where this is appropriate. Within this framework, the development of the numerous institutes at the University of Michigan was reviewed to show that categorical centers can suitably be organized within individual departments, by interdepartmental arrangements, as an independent entity within one of the schools of the university, or in a collaborative organization involving more than one school. It was indicated that administrative patterns cannot be examined in the abstract but only as a means of bringing a specific group of people together in order to reinforce each other's efforts towards a preconceived goal. The concurrent need to safeguard the departmental organization of the university for the continued replication of trained investigators was stressed. The major problem envisaged for the categorical institutes was how to maintain continuity and permanence while they were needed and how to terminate them when their specific mission was completed or abandoned. In summarizing his position, Dr. Hubbard indicated that he favored mission-oriented institutes within a university, ready to contribute to it, and endowed with autonomy within the framework of the whole.

Dr. Stetten offered his support for these general recommendations after a review of his personal experience both within and outside the National Institutes of Health. The problems inherent in the long-term maintenance of professional personnel and their morale in categorical institutes not affiliated with teaching institutions were discussed against the backdrop of the desire motivating most research men to perpetuate their ideas and their impact on science by teaching and training younger scientists. It was emphasized that collaboration among researchers for multidisciplinary or categorical purposes can only be encouraged, not enforced, and that continued stable support for good investigators everywhere provided the best hope for progress of research on this as on other major problems. A distinction must be drawn between research and development, the former being the proper objective of academic institutions. Within the framework of these considerations, the setting up of the categorical centers under discussion within established teaching institutions was favored.

Dr. Gilman contrasted the three years during World War II he spent in categorical interdisciplinary research with more than two decades in academic life. Despite the intrinsic interest and importance of the problems investigated during the war years, the association with outstanding colleagues, the availability of adequate equipment, the productivity and satisfactions of the research from the point of view of results and publications, it was concluded that the separation from the university environment and from teaching presented an almost unsurmountable obstacle.
to long-term contentment and motivation. It was emphasized that research and teaching are inseparable, that categorical institutes concerned with the fundamental aspects of a problem such as carcinogenesis can make a tremendous contribution to the teaching and research strength of a university, but that such institutes would most appropriately be placed in academic institutions which had strong research interests and trained personnel consonant with the categorical objectives to be met. As an illustration, the current development at Einstein of a broad institute on mental retardation was shown to be feasible because of the long-term existence of strong faculty interest and expertise in the various disciplines impinging on this particular problem.

Speaking from the point of view of a medical school department chairman, Dr. Bean stressed that the precise system of organization to be devised seemed less important than the bringing together of the right people with the right ideas. Misgivings were expressed with regard to the successful integration of a categorical carcinogenesis institute into a clinical program concerned with patient care and with the education of medical students. The need to guard in general against overspecialization and concentration on specific aspects of a problem at the expense of concern for the whole patient was emphasized.

Dr. Rhedin endorsed the desirability of having categorical programs associated with a medical school or university, particularly with regard to recruitment and maintenance of professional staff. It was felt that in smaller medical schools the best arrangement might be an interdepartmental affiliation whereas in the larger schools there might be room for intradepartmental groups as well. It was deemed important to guard against overorganization and rigidity in developing the objectives of the program and assigning investigators to them.

Dr. Zamecnik alluded to the work actively going forward in various laboratories on carcinogenesis, chemical and viral, and expressed reservations with regard to a large increase in research effort on this single problem in the face of the current leveling off of the available fiscal support for research in general. It was felt that the existing pattern of individual project support by the extramural grants system continued to hold the best promise for progress and accomplishment and that overemphasis on directed categorical targets must not be allowed to threaten existing programs.

GENERAL DISCUSSION

Consideration was given to the general question whether at this juncture there is a real necessity for concentration of efforts on a specific disease, i.e., whether categorical research is a justifiable objective. It was felt that the magnitude and urgency of the problem required continued emphasis on cancer research as such. It was deemed desirable by several participants to define the objectives of the mission-oriented research
broadly enough so that growth, inspiration, and change would not be stifled. A plea was made by others for more extensive integration and correlation of laboratory findings and advances with the development of preventive measures at the population level.

It was agreed that, at least at the postdoctoral level, there was no reluctance on the part of cancer researchers to participate in the teaching and training functions of their universities. The desirability of continued association of research and teaching activities was endorsed.

With regard to the specific question whether there was a need for multidisciplinary efforts in chemical carcinogenesis, Dr. Gellhorn listed the pertinent recommendations of several of the other panels which had met earlier and pointed out that the groups concerned with epidemiology, in vitro systems, communication, and service facilities and reference standards had independently offered their endorsement of the creation of multidisciplinary centers. The question was then raised how the National Cancer Institute envisaged support for these new efforts, if they were approved.

Dr. Endicott indicated informally that implementation of these activities would probably require non-matching building funds for physical facilities, a commitment on the part of the parent institution as well as the granting agency for long-term stability of a particular program, and new review mechanisms to assess initially the capability of an institution to organize and manage such a project and later the overall productivity and quality of the research effort.

Vigorous discussion then touched upon the wide spectrum of activities which might be encompassed within the proposed program, from the most fundamental problems of mechanisms at the molecular level to the most applied levels of testing of potential environmental hazards and the design of appropriate preventive measures. It was generally agreed that many of these activities would be the proper concern of centers within a university setting while others would more appropriately and expeditiously be carried out in other types of organizational structures. It was also concluded that a particular center devoted to a particular approach would find a suitable home in one academic institution but not necessarily in another and that this consideration would clearly have to be included in the planning.

SPECIFIC RECOMMENDATIONS

1. On the basis of preliminary reports from expert panels on chemical carcinogenesis, it was recognized that multidisciplinary centers devoted to various research aspects in this field are an appropriate and desirable mechanism for the attainment of current objectives.

2. The establishment of a research institute within a university or medical school is an asset when the interests and skills of the existing staff constitute a dynamic nucleus and the following conditions are met.
3. A research institute should have a geographical location rather than being diffused throughout the parent institution.

4. In order to avoid parasitism of the university or medical school, the research institute should have
   a) a long-term, realistic, self-supporting budget to cover the entirety of its expenditures,
   b) a training program for investigators so that it will enrich the scientific manpower pool rather than drain it.

5. The professional staff of the research institute should be integrated into the teaching program of the parent institution according to the desires and competence of the staff.

6. A viable mechanism for academic recognition and advancement of the staff of the research institute should be formally established. Patterns might vary among institutions, but a favored suggestion was a dual appointment in the research institute and in the discipline of the investigator's training. Academic advancement need not necessarily be parallel in each appointment. The research institute should have autonomy in its appointments and recommendations for advancement should proceed through the ordinary channels established by the institution.

7. There should be ready and flexible mechanisms for collaborative research of the institute staff with members of other academic departments.

8. A critical size appropriate to the scope of the research objectives should be attained in the institute.

9. Mechanisms should be considered for termination or redirection of the research institute if it has completed its mission or has stagnated.

10. These recommendations relate particularly to the more fundamental aspects of research in chemical carcinogenesis, which are most appropriately the concern of the academic community. Within this framework, categorical research institutes hold promise for expanded and accelerated progress in chemical carcinogenesis as well as in other major areas of cancer research. These conclusions should not be construed to exclude the establishment of alternative mechanisms for the pursuit of the more applied and developmental aspects of the general problem.
Participants, American Association of Cancer Institutes Meeting
May 25, 1970, Houston, Texas

Gentlemen:

Although we have not heard from the entire group in the photograph with attached overlay sent to you on June 19, 1970, I am pleased to send you the captions we have received for the photograph.

With every good wish and many thanks for your participation.

Sincerely yours,

Robert C. Hickey, M.D.
Executive Vice President and Director

RCH/jw

enclosure
CAPTIONS
GROUP PHOTOGRAPH

AMERICAN ASSOCIATION OF CANCER INSTITUTES
MAY 25, 1970 HOUSTON, TEXAS

1. Robert C. Hickey, M.D.
   Executive Vice President and Director
   The University of Texas
   M. D. Anderson Hospital and Tumor Institute
   Houston, Texas 77025

2. Edwin A. Mirand, M.D.
   Associate Institute Director & Professor
   Roswell Park Memorial Institute
   666 Elm Street
   Buffalo, New York 14203

3. R. Lee Clark, M.D.
   President
   The University of Texas
   M. D. Anderson Hospital and Tumor Institute
   Houston, Texas 77025

4. Dr. N. N. Blokhin
   Institute of Experimental & Clinical Oncology
   Academy of Medical Sciences
   Kashirskoe Shosse 6
   Moscow B-409 U.S.S.R.

5. Frank L. Horsfall, Jr., M.D.
   President and Director
   Sloan-Kettering Institute for Cancer Research
   444 East 68 Street
   New York, New York 10021

6. Mrs. Antonio Pinto Viera
   Rio de Janeiro, Guanabara, Brazil

7. Mrs. Frank L. Horsfall
   New York, New York

8. Michael J. Brennan, M.D.
   President
   The Michigan Cancer Foundation
   4811 John R. Street
   Detroit, Michigan 48201

9. Gerald P. Murphy, M.D.
   Acting Director
   Roswell Park Memorial Institute
   666 Elm Street
   Buffalo, New York 14203
10. Dr. John Higginson, Director
International Agency for
Research on Cancer
16, Avenue Maréchal Foch
69 Lyon (6ème) France

11. Prof. A.I. Rakov
Prof. Petrov Research Institute
Leningrad-Pesochny-2 U.S.S.R.

12. Dr. André Lwoff
Ministère de l'Éducation Nationale
Institut de Recherches Scientifiques sur le Cancer
15, Avenue Vaillant-Courrier
94 - Villejuif, France

13. M.G.P. Stoker, M.D., F.R.S.
Director of Research
Imperial Cancer Research Fund
Lincoln's Inn Fields
London, W.C.2. England

14. Dr. H. Isliker
Swiss Institute for Experimental
Cancer Research
1005 Lausanne Switzerland

15. Dr. Eric C. Easson
Director of Radiotherapy
Christie Hospital & Holt Radium Institute
Withington, Manchester 20 England

16. Timothy R. Talbot, Jr., M.D.
Director
The Institute for Cancer Research
7701 Burholme Avenue
Fox Chase
Philadelphia, Pennsylvania 19111

17. Prof. I. Shevelev
Director of Kiev Research Institute of Rontgenology
Radiology & Oncology, Tomenaweb 71, Kiev 25 USSR

18. Professor Dr. Med. Erik Poppe
Det Norske Radiumhospital
Alminnelig Avdeling
Montebello
Oslo 3 Norway
19. **Prof. Ercole Sega**  
   Chief, Laboratory of Immunology  
   Regina Elena Cancer Institute  
   Via Regina Elena 2 91  
   Rome, Italy

20. **Giampiero di Mayorca, M.D.**  
   Professor of Microbiology  
   The Eppley Institute  
   for Research in Cancer  
   University of Nebraska Medical Center  
   42nd and Dewey Avenue  
   Omaha, Nebraska 68105

21. **Dr. Antonio Pinto Vieria**  
   National Cancer Institute  
   Praca Cruz Vermelha 23  
   Rio de Janeiro, Guanabara, Brazil

22. 

23. **O. Costa Mandry, M.D.**  
   Medical Director  
   Hospital Dr. I. Gonzalez Martinez  
   de la Liga Puertorriquenz Contra el Cancer  
   Apartado Postal 1811 Hato Rey  
   Puerto Rico

24. **Dr. Bela J. J.**  
   Omaha, Neb.

25. **Prof. Dr. Herwig Hamperl**  
   Pathologisches Institut der Universität Bonn  
   53 Bonn-Venusberg, Germany

26. **Roger Daoust, Ph.D., Director**  
   Montreal Cancer Institute  
   Notre-Dame Hospital  
   Montreal 133, Canada

27. **Prof. L. Aboul Nasr**  
   Cancer Institute, Faculty of Medicine  
   University of Cairo  
   Kasr el - Aini Street  
   Cairo, U.A.R. Egypt
28. A. R. Curreri, M.D., Chairman  
   Department of Surgery  
   Director, Division of Clinical Oncology  
   University of Wisconsin Medical Center  
   1300 University Avenue  
   Madison, Wisconsin 53706

29.

30.

31. Dr. John S. Spratt, Jr., Director  
   Ellis Fishel Cancer Hospital  
   and Cancer Research Center  
   Business Loop 70 and Garth Avenue  
   Columbia, Missouri 65201

32. Dr. J.H.C. Ho  
   Senior Specialist (Radiology)  
   M. & H.D. Institute of Radiology  
   Queen Elizabeth Hospital  
   Kowloon, Hong Kong

33. Paul T. Condit, M.D., Ph.D.  
   Head, Cancer Section  
   Oklahoma Medical Research Foundation  
   825 N.E. 13th Street  
   Oklahoma City, Oklahoma 73104

34. Dr. Frances T. Kenney  
   Oak Ridge National Laboratory  
   Oak Ridge, Tennessee

35. Dr. M. Gaitan-Yanguas  
   Director  
   Instituto Nacional de Cancerologia  
   Bogota, Colombia, S.A.

36. Prof. Dr. E. Hecker  
   Deutsches Krebsforschungszentrum  
   Stiftung Des Öffentlichen Rechts  
   Der Vorsitzende des Direktoriums  
   Berliner Strasse 21  
   69 Heidelberg, Germany
37. Carl G. Baker, M.D.  
   Director  
   National Cancer Institute  
   National Institutes of Health  
   Bethesda, Maryland 20014

39. Dr. Octave Costachel  
   Bucharest Oncological Institute  
   Ministry of Health and Social Welfare  
   Boulevard 1 Mai No. 11  
   Bucharest, Romania

40. Professeur M. Dargent  
   Directeur du Centre  
   Centre Regional de Lutte Contre le Cancer  
   Centre Leon Berard  
   28, Rue Laennec  
   69 Lyon (8e) France

41. Dennis V. Razis, M.D.  
   Scientific Director  
   Diagnostic & Therapeutic  
   Institute of Piraeus  
   Mataxas Memorial  
   51 Botassi St.  
   Piraeus 30, Greece

42. Richard H. Bottomley, M.D.  
   Assistant Head, Cancer Section  
   Oklahoma Medical Research Foundation  
   Oklahoma City, Oklahoma

43. Prim. Zeljko Maričić, M.D.  
   Director  
   Central Institute for Tumors and Allied Diseases  
   Zagreb, Ul. X. Korpusa bb,  
   Yugoslavia

44. Eduardo Caceres, M.D., F.A.C.S.  
   Director  
   Instituto Nacional de Enfermedades Neoplasicas  
   Avenida Alfonso Ugarte 825  
   Lima Peru
45. Ing. Vesna Dragičević, M.D.
Liga za borbu protiv raka SRH
(League for the Fight Against Cancer of Croatia)
Zagreb, Ul. X. Korpusa bb,
Yugoslavia

46. Sidney Farber, M.D.
Director of Research
The Children's Cancer Research Foundation
35 Binney Street
Boston, Massachusetts 02115

47. Walter J. Burdette, M.D., Ph.D.
Associate Director (Research)
The University of Texas
M. D. Anderson Hospital
and Tumor Institute
Houston, Texas 77025

48. Harold P. Rusch, M.D.
Director
McArdle Laboratory for Cancer Research
University of Wisconsin
1300 University Avenue
Madison, Wisconsin 53706

49. Robert O. Johnson, M.D.
Director
Division of Clinical Oncology
The University of Wisconsin
University Hospitals
Madison, Wisconsin 53706

50.

51.

52. Robert M. Taylor, M.D.
Secretary-General UICC
National Cancer Institute of Canada
25 Adelaide Street East
Toronto 1, Ontario Canada
53. Prof. Dr. O. Mühlbock
   Antoni Van Leeuwenhoek-Huis
   Het Nederlands Kankerinstituut
   Amsterdam C
   Sarphatistraat 108
   Netherlands

54. Prof. E. Lima-Basto
   President
   Instituto Portugues Oncologia
   Palhava, Lisbon Portugal

55. Murray M. Copeland, M.D.
   Vice President
   University Cancer Foundation
   The University of Texas
   M. D. Anderson Hospital
   and Tumor Institute
   Houston, Texas 77025

56. Masao Yokoyama, M.D.
   Experimental Pathology Section
   The University of Texas
   M. D. Anderson Hospital
   and Tumor Institute
   Houston, Texas 77025

57. Tomizo Yoshida, M.D.
   Director
   Cancer Institute
   (Japanese Foundation for Cancer Research)
   Nishi-Sugamo, Toshimu-Ku
   Tokyo, Japan

58. Tokuji Ichikawa, M.D.
   Director
   The First National Hospital of Tokyo
   1, Toyama, Shinjuku-Ku
   Tokyo, Japan

59. Mrs. Yoko Sugiura
   New York, New York

60. Prof. Dr. C. G. Schmidt, President
    Deutscher Zentralausschuss für
    Krebsbekämpfung und Krebsforschung e.V.
    Hufelandstrasse 55, Klinikum
    43 Essen, Germany
61.

62. Mrs. Dr. Hannelore Schmidt
    Essen, Germany
CROSS REFERENCE

See File Consultant on Cancer

for Pertinent Information Described below:

Letter _______ Memo _______ Other V

Members of AACI

From _______ To _______

Date _______

Subject Re: Material on each institution to be included in report to Panel.
Minutes

Association of American Cancer Institutes

M. D. Anderson Hospital and Tumor Institute, Houston, Texas

May 25, 1970

Dr. Hickey opened the meeting at the M. D. Anderson Library and Dr. Clark welcomed the many foreign institute directors or their representatives. Dr. Clark stressed the purpose of the organization and its usefulness.

Dr. Horsfall presided as President of the Association of American Cancer Institutes and again re-stated how beneficial the AACI was to the cancer institute directors.

Dr. Horsfall asked that the minutes of the Buffalo meeting of the Association held November 2-3, 1969, be accepted and they were so accepted.

Dr. Horsfall then called upon Dr. Mirand to review, for the benefit of the foreign guests, the number of institutes which are members of the Association of American Cancer Institutes. Dr. Mirand advised there were 22 American cancer institutes participating in the AACI. Dr. Mirand also reported that 93 foreign institute directors were contacted and invited to meet with the AACI at the M. D. Anderson Hospital and Tumor Institute at the time of the Xth International Cancer Congress. He reviewed the responses as follows: 41 said yes, they would attend; 21 said no; and no response was received from 31.

Dr. Mirand noted that he had received resignations from the Association of American Cancer Institutes from Dr. Alfred Gellhorn, Dean of the School of Medicine at the University of Pennsylvania; Dr. Leonard P. Eliel of the
Oklahoma Medical Research Foundation who is now the Director of the University of Oklahoma Medical Center's Graduate and Research Affairs; Dr. A. R. Curreri, Director of the Division of Clinical Oncology, University of Wisconsin Medical Center, Madison; and Mr. Russell E. Merritt from the Cancer Research Center, Columbia, Missouri.

Dr. Paul T. Condit, Head of the Cancer Section, Oklahoma Medical Research Foundation, will replace Dr. Eliel as their representative while Dr. Robert O. Johnson, Director of the Division of Clinical Oncology, will replace Dr. Curreri as the member of the Association representing the University of Wisconsin Medical Center. Dr. Curreri will continue to serve as an alternate. Dr. Harry D. Brown will serve as an alternate for the Cancer Research Center, Columbia, Missouri.

Dr. Mirand reported that 20 of the 22 cancer institutes had donated or committed to donate $100 for the social-scientific affair honoring the foreign institute directors and representatives. He stated 15 institutes had paid, 5 promised to pay, and 2 institutes were unable to contribute. At the time of the meeting, the Treasury of AACI contained $1500 and this appeared to be ample to cover the expenses of the meeting.

Dr. Mirand then called for Dr. Owens to go over the plans for the fall meeting of the Association but Dr. Owens was not in attendance. Therefore, the date for the fall meeting could not be finalized but the meeting will be held at Johns Hopkins in Baltimore, perhaps October 18-20, 1970.

Several of the foreign institute directors made comments during the meeting. For instance, Prof. N. N. Blokhin from the USSR stressed that at the next meeting of the IUCC we should arrange a formal session for all cancer institute directors in the world. He said that the USSR had 22 cancer institutes.
8/31/70
Per request of Mrs. Kolenda I typed this up and sent a copy to MMC. He didn't have current names and needed to write them per RLC's request for info. for the panel report.

br
Dr. Ercole Sega from Italy thanked the Association for inviting him and hoped that the IUCC meeting could be in Florence. He asked what our association was with the American Association for Cancer Research. At that time, Dr. Baker requested Dr. Horsfall to explain, in addition, the American Cancer Society and the AACR since there might be some confusion there, too, for the foreign guests. Dr. Horsfall related that we had no formal association with the American Cancer Society or the American Association for Cancer Research.

Dr. M. Gaitan Yanguas from Bogota, Colombia, wanted to know if we had any association with the American Hospital Association and Dr. Horsfall said we did not.

Dr. Talbot proceeded to say that the Association of American Cancer Institutes is a very informal group and we don't even collect dues.

Dr. John Higginson from Lyon, France, stated that he plans to have the cancer institute directors meet in Lyon, France, to discuss mutual problems and stressed that this would be of great value.

Dr. Hickey stressed that we all should see the typical hospital room at the Exhibit.

Dr. Horsfall, in closing the meeting, thanked the foreign guests for attending the meeting and hoped that we could arrange in the future some interchange between the Association of American Cancer Institutes and their respective institutes.

Dr. Horsfall then invited all the foreign and U. S. A. cancer institute directors or their representatives to a reception and buffet-dinner at the Anderson-Mayfair Hotel. This proved to be a very successful affair.
The expenses for the reception and buffet-dinner were paid by fees collected from the various Institute members of the AACI. The expenses totaled $827.40. Dr. Mirand paid these bills for the Association at the request of Dr. Hickey who submitted final receipts. Appropriate checks were made out to the M. D. Anderson Hospital for a total of $147.40 to cover postage, photographs and mailers, and the printing of invitations. A check in the amount of $680.00 was also made payable to the Anderson-Mayfair Hotel to cover the expenses for the reception and buffet-dinner.

E. A. Mirand
Secretary-Treasurer, AACI
AACI members

BAKER, CARL G., M.D.
Acting Director
National Cancer Institute
National Institutes of Health
Bethesda, Maryland 20014

Clark, R. Lee

Grace, Dr. James T. - would use acting I guess

Shubik, Dr. Philippe
Director
Eppley Institute for Research in Cancer
The University of Nebraska College of Medicine
42nd and Dewey Avenue
Omaha, Nebraska 68105

Weinhouse, Sidney, Ph.D.
Fels Research Institute
Temple University School of Medicine
Philadelphia, Pennsylvania 19140

Farber, Sidney, M.D.
Children's Cancer Research Foundation
35 Binney Street
Boston, Massachusetts 02115

Horsfall, Jr., Frank L., M.D.
Sloan-Kettering Institute for Cancer Research
New York, New York 10021

Gottschalk, Alexander, M.D.
950 E. 59th Street
Department of Radiology
Chicago, Illinois 60637

Gellhorn, Dr. Alfred
Dean, School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania 19104

Eliel, Leonard P., M.D.
Oklahoma Medical Research Institute
825 Northeast Thirteenth Street
Oklahoma City, Oklahoma 73104
Wood, Dr. David A.
Cancer Research Institute
University of California School of Medicine
San Francisco, California 94122

Talbot, Jr., T. R., M.D.
The Institute for Cancer Research
7701 Burholme Avenue
Fox Chase
Philadelphia, Pennsylvania 19111

Spratt, Jr., John S., M.D.
Ellis Fischel State Cancer Hospital
Columbia, Missouri 75201

Warren, Shields, M.D.
Cancer Research Institute
New England Deaconess Hospital
194 Pilgrim Road
Boston, Massachusetts 02215

Grotzinger, Paul J., M.D.
2121 Valley Road
Huntingdon Valley, Pennsylvania 19006

Simpson, William L., M.D.
Detroit Institute of Cancer Research
4811 John R. Street
Detroit, Michigan 48201

Rusch, Harold F., M.D.
McArdle Memorial Laboratory
The University of Wisconsin
The Medical School
Madison, Wisconsin 53706

Liverman, James P., Ph.D.
Oak Ridge National Laboratory
Biology Division
Post Office Box Y
Oak Ridge, Tennessee 37830

Lemon, Henry M., M.D.
Division of Oncology
Department of Internal Medicine
The University of Nebraska
Medical Center
42nd and Dewey Avenue
Omaha, Nebraska 68105
Skipper, Dr. Howard E.
Vice President and Director of
the Kettering-Meyer Laboratories of
Southern Research Institute
Birmingham, Alabama

Curreli, A. R., M.D.
Clinical Oncology Division
Department of Surgery
Medical School
University of Wisconsin
Madison, Wisconsin 53706

Bodily, Howard, Ph.D.
State Department of Public Health
Bureau of Chronic Diseases
2151 Berkeley Way
Berkeley, California 94704
Participants, American Association of Cancer Institutes Meeting
May 25, 1970, Houston, Texas

Gentlemen:

Enclosed herewith are several photographs taken at the meeting of the American Association of Cancer Institutes in Houston.

We hope you will enjoy them.

I believe all present felt this a memorable occasion.

The large group photograph lacks complete individual identifications. To avoid any error, we would appreciate it if you would identify yourself on the overlay attached to the photograph, and return your identification number to my office. We shall then mail the captions to each of you.

To the American Association of Cancer Institutes members, we appreciated your participation and to all guests--return:

Very truly yours,

Robert C. Hickey, M. D.
Executive Vice President
and Director

RCH/jw
enclosure
Minutes

Association of American Cancer Institutes

M. D. Anderson Hospital and Tumor Institute,
Houston, Texas

May 25, 1970

Dr. Mickey opened the meeting at the M. D. Anderson Library and
Dr. Clark welcomed the many foreign institute directors or their repre-
sentatives. Dr. Clark stressed the purpose of the organization and its
usefulness.

Dr. Horsfall presided as President of the Association of American
Cancer Institutes and again re-stated how beneficial the AACI was to the
cancer institute directors.

Dr. Horsfall asked that the minutes of the Buffalo meeting of the
Association held November 2-3, 1969, be accepted and they were so accepted.

Dr. Horsfall then called upon Dr. Mirand to review, for the benefit of
the foreign guests, the number of institutes which are members of the
Association of American Cancer Institutes. Dr. Mirand advised there were
22 American cancer institutes participating in the AACI. Dr. Mirand also
reported that 93 foreign institute directors were contacted and invited to
meet with the AACI at the M. D. Anderson Hospital and Tumor Institute at
the time of the Xth International Cancer Congress. He reviewed the responses
as follows: 41 said yes, they would attend; 21 said no; and no response was
received from 31.

Dr. Mirand noted that he had received resignations from the Association
of American Cancer Institutes from Dr. Alfred Gellhorn, Dean of the School
of Medicine at the University of Pennsylvania; Dr. Leonard P. Eliel of the
Oklahoma Medical Research Foundation who is now the Director of the University of Oklahoma Medical Center’s Graduate and Research Affairs; Dr. A. R. Currier, Director of the Division of Clinical Oncology, University of Wisconsin Medical Center, Madison; and Mr. Russell E. Merritt from the Cancer Research Center, Columbia, Missouri.

Dr. Paul T. Condit, Head of the Cancer Section, Oklahoma Medical Research Foundation, will replace Dr. Eliel as their representative while Dr. Robert O. Johnson, Director of the Division of Clinical Oncology, will replace Dr. Currier as the member of the Association representing the University of Wisconsin Medical Center. Dr. Currier will continue to serve as an alternate. Dr. Harry D. Brown will serve as an alternate for the Cancer Research Center, Columbia, Missouri.

Dr. Mirand reported that 20 of the 22 cancer institutes had donated or committed to donate $100 for the social-scientific affair honoring the foreign institute directors and representatives. He stated 15 institutes had paid, 5 promised to pay, and 2 institutes were unable to contribute. At the time of the meeting, the Treasury of AACI contained $1500 and this appeared to be ample to cover the expenses of the meeting.

Dr. Mirand then called for Dr. Owens to go over the plans for the fall meeting of the Association but Dr. Owens was not in attendance. Therefore, the date for the fall meeting could not be finalized but the meeting will be held at Johns Hopkins in Baltimore, perhaps October 18-20, 1970.

Several of the foreign institute directors made comments during the meeting. For instance, Prof. N. N. Blokhin from the USSR stressed that at the next meeting of the IUCC we should arrange a formal session for all cancer institute directors in the world. He said that the USSR had 22 cancer institutes.
Dr. Ercole Sega from Italy thanked the Association for inviting him and hoped that the IUCC meeting could be in Florence. He asked what our association was with the American Association for Cancer Research. At that time, Dr. Baker requested Dr. Horsfall to explain, in addition, the American Cancer Society and the AACR since there might be some confusion there, too, for the foreign guests. Dr. Horsfall related that we had no formal association with the American Cancer Society or the American Association for Cancer Research.

Dr. M. Gaitan Vanguas from Bogota, Colombia, wanted to know if we had any association with the American Hospital Association and Dr. Horsfall said we did not.

Dr. Talbot proceeded to say that the Association of American Cancer Institutes is a very informal group and we don't even collect dues.

Dr. John Higginson from Lyon, France, stated that he plans to have the cancer institute directors meet in Lyon, France, to discuss mutual problems and stressed that this would be of great value.

Dr. Hickey stressed that we all should see the typical hospital room at the Exhibit.

Dr. Horsfall, in closing the meeting, thanked the foreign guests for attending the meeting and hoped that we could arrange in the future some interchange between the Association of American Cancer Institutes and their respective institutes.

Dr. Horsfall then invited all the foreign and U. S. A. cancer institute directors or their representatives to a reception and buffet-dinner at the Anderson-Mayfair Hotel. This proved to be a very successful affair.
The expenses for the reception and buffet-dinner were paid by fees collected from the various Institute members of the AACI. The expenses totaled $827.40. Dr. Mirand paid these bills for the Association at the request of Dr. Hickey who submitted final receipts. Appropriate checks were made out to the M. D. Anderson Hospital for a total of $147.40 to cover postage, photographs and mailers, and the printing of invitations. A check in the amount of $680.00 was also made payable to the Anderson-Mayfair Hotel to cover the expenses for the reception and buffet-dinner.

E. A. Mirand
Secretary-Treasurer, AACI
Dr. Carl Baker, Acting Director - Member, AACI
National Cancer Institute
National Institutes of Health
Bethesda, Maryland 20014

Richard Ballard - guest
Oklahoma Medical Research Foundation
Oklahoma City
Oklahoma

Dr. Michael J. Brennan - Member, AACI
Medical and Scientific Director
The Michigan Cancer Foundation
4011 John R. Street
Detroit, Michigan 48201

Dr. Walter J. Banta - Guest
Associate Director (Research)
M. D. Anderson Hospital and Tumor Institute
Texas Medical Center
Houston, Texas 77025

Dr. R. Lee Clark, President - Member, AACI
The University of Texas at Houston
M. D. Anderson Hospital and Tumor Institute
Texas Medical Center
Houston, Texas 77025

Dr. Paul T. Condit - Member, AACI
Chair, Cancer Section
Oklahoma Medical Research Foundation
825 Northeast Thirteenth Street
Oklahoma City, Oklahoma 73104

Dr. Murry M. Copeland, Vice-President - Alternate, AACI
University Cancer Foundation
The University of Texas at Houston
M. D. Anderson Hospital and Tumor Institute
Houston, Texas 77025

Dr. A. R. Currier, Chairman - Member, AACI
Department of Surgery
Director, Division of Clinical Oncology
University of Wisconsin Medical Center
1300 University Avenue
Madison, Wisconsin 53706
Dr. G. di Mayorca - Alternate, AACI
Ripley Institute for Research in Cancer
Omaha, Nebraska

Dr. Sidney Farber - Member, AACI
Director of Research
The Children's Cancer Research Foundation, Inc.
35 Binney St.
Boston, Massachusetts 02115

Dr. Robert C. Mickey - Alternate, AACI
Executive Vice President and Director
The University of Texas M. D. Anderson Hospital and Tumor Institute
Texas Medical Center
Houston, Texas 77025

Dr. Frank L. Horsfall, Jr. - Member, AACI
President and Director
Sloan-Kettering Institute for Cancer Research
444 East 68th Street
New York, New York 10021

Dr. Robert O. Johnson - Guest
University of Wisconsin
Madison, Wisconsin

Dr. P. T. Kenney - Guest
Oak Ridge National Laboratory
Oak Ridge, Tennessee

Dr. Edwin A. Miranda - Alternate, AACI
Associate Institute Director
Roswell Park Memorial Institute
688 Elm Street
Buffalo, New York 14203

Dr. Robert A. Marston - Guest
Vice President for Professional and Public Affairs
The University of Texas M. D. Anderson Hospital and Tumor Institute
Houston, Texas 77025

Dr. Gerald P. Murphy - Guest
Roswell Park
Buffalo, New York

Dr. Harold P. Rusch, Director - Member, AACI
Maggio Laboratory for Cancer Research
University of Wisconsin
1300 University Avenue
Madison, Wisconsin 53706
Dr. John S. Spratt, Jr., Director - Member, AACI
Ellis Fischel Cancer Hospital and Cancer Research Center
Business Loop 70 and Garth Avenue
Columbia, Missouri 65201

Dr. Timothy R. Talbot, Jr., Director - Member, AACI
The Institute for Cancer Research
7701 Burholme Avenue
Fox Chase
Philadelphia, Pennsylvania 19111

Dr. Bela Toth - Guest
Eppler Institute
University of Nebraska
Omaha, Nebraska

Dr. Masaio Yoguyama - Guest
The University of Texas
M. D. Anderson Hospital and Tumor Institute
Texas Medical Center
Houston, Texas 77025

Dr. David A. Wood, Director - Member, AACI
Cancer Research Institute
University of California
Medical Center
San Francisco, California 94122
INVITATIONS SENT TO FOREIGN INSTITUTES
THOSE IN ATTENDANCE
AACI MEETING - MAY 25, 1970

Dr. N. N. Alexandrov
Institute of Oncology and Radiology
of Belorussian
Minsk U.S.S.R.

Prof. E. Lima Basto, President
Instituto Portugueses Oncologia
Palhava, Lisbon, Portugal

Dr. N. N. Blokhin
Institute of Experimental & Clinical Oncology
Academy of Medical Sciences
Kashirskoe Shosse 6
Moscow B-409 U.S.S.R.

Dr. Eduardo Caceres, Director
Instituto Nacional de Enfermedades Neoplasicas
Avenida Alfonso Ugarte 825
Lima, Peru

Dr. Octav Costache
Bucharest Oncological Institute
Ministry of Health and Social Welfare
Boulevard 1 Mai No. 11
Bucharest, Romania

Dr. O. Costa-Mandry, Medical Director
I Gonzalez Martinez Oncologic Hospital
Puerto Rico Medical Center
Box 1811
Hato Rey, Puerto Rico

Roger Dacost, Ph.D., Director
Montreal Cancer Institute
Notre-Dame Hospital
Montreal 133, Canada

Dr. Marcel Dargent
Centre Leon Berard
28, Rue Laennec
F. 69 Lyon 8, France

Prof. Dr. Herwig Hamperl
Pathologisches Institut der Universitat Bonn
53 Bonn-Venusberg, Germany

Dr. E. Hecker (Representing Prof. K. H. Bauer)
German Centre for Cancer Research
Berliner Strasse 23
D 69 Heidelberg, Germany
INVITATIONS TO FOREIGN INSTITUTES

PAGE 2

AACI INFORMAL MEETING

Professor Sir Alexander Haddow
Institute of Cancer Research
Royal Cancer Hospital
University of London
Fulham Road
London, W. N. 3, United Kingdom

Dr. John Higginson, Director
International Agency for Research on Cancer
16, Avenue Marsechal Foch 69
Lyon, France

Dr. J. H. C. Ho
M. H. D. Institute of Radiology
Queen Elizabeth Hospital
Kowloon, Hong Kong

Dr. T. Ichikawa, Director
The First National Hospital of Tokyo
1, Toyama-cho, Shinjuku-ku
Tokyo, Japan

Dr. H. Ialiker, Director
Institut Suisse de Recherches Experimenetales sur le Cancer
Bignon 21, 22
1205 Lausanne, Switzerland

Dr. T. Koszarowski, Director
Curie Institute of Oncology
Warsaw, Poland

Dr. André Lwoff
Centre de Recherches sur la Cellule Normale et Cancereuse
16, Avenue P. Vallant-Couturier
94 Villejuif, France

Prof. O. Muhlbock
Netherlands Institute for Cancer Research
Antoni van Leeuwenhoek-Huis
Sarphatistraat 108
Amsterdam C, Netherlands

Prof. A. L. Nasr
Cancer Institute, Faculty of Medicine
University of Cairo
Kasr el - Aini Street
Cairo, U. A. R. Egypt

Dr. Erik Poppe
The Norwegian Radium Hospital
Montebello - Oslo 3, Norway
Dr. T. Yoshida, Director
Cancer Institute
Japanese Foundation for Cancer Research
2615, Nishisumido 2-chome, Toshima-ku
Tokyo, Japan

Dr. Michel Vandeputte
General Secretary
European Association for Cancer Research
First Congress
Brussels, Belgium

Dr. M. Gaitan Vargas
Director, Instituto Nacional de Cancerologia
Bogota, Columbia

Dr. Dragicene Vaong
Tumor Institute
Zagreb, Yugoslavia

Dr. Marinic Seljko
Tumor Institute
Zagreb, Yugoslavia

Representing Dr. Ivo Padovon, Tumor Institute
Zagreb, Yugoslavia
MAY 28, 1970

AACI INFORMAL MEETING
MEMBERS AND ALTERNATES
and INVITED GUESTS
THOSE IN ATTENDANCE

ASSOCIATION OF AMERICAN CANCER INSTITUTES

Dr. Carl Baker, Acting Director - Member, AACI
National Cancer Institute
National Institutes of Health
Bethesda, Maryland 20014

Richard Ballard - guest
Oklahoma Medical Research Foundation
Oklahoma City
Oklahoma

Dr. Michael J. Brennan - Member, AACI
Medical and Scientific Director
The Michigan Cancer Foundation
4811 John R. Street
Detroit, Michigan 48201

Dr. Walter J. Burdette - Guest
Associate Director (Research)
M. D. Anderson Hospital and Tumor Institute
Texas Medical Center
Houston, Texas 77025

Dr. R. Lee Clark, President - Member, AACI
The University of Texas at Houston
M. D. Anderson Hospital and Tumor Institute
Texas Medical Center
Houston, Texas 77025

Dr. Paul T. Condit - Member, AACI
Head, Cancer Section
Oklahoma Medical Research Foundation
825 Northeast Thirteenth Street
Oklahoma City, Oklahoma 73104

Dr. Murray M. Copeland, Vice-President - Alternate, AACI
University Cancer Foundation
The University of Texas at Houston
M. D. Anderson Hospital and Tumor Institute
Houston, Texas 77025

Dr. A. R. Curreri, Chairman - Member, AACI
Department of Surgery
Director, Division of Clinical Oncology
University of Wisconsin Medical Center
1300 University Avenue
Madison, Wisconsin 53706
Dr. G. di Mayorca - Alternate, AACI
Eppley Institute for Research in Cancer
Omaha, Nebraska

Dr. Sidney Farber - Member, AACI
Director of Research
The Children's Cancer Research Foundation, Inc.
35 Binney St.
Boston, Massachusetts 02115

Dr. Robert C. Hickey - Alternate, AACI
Executive Vice President and Director
The University of Texas M. D. Anderson Hospital and Tumor Institute
Texas Medical Center
Houston, Texas 77025

Dr. Frank L. Horsfall, Jr. - Member, AACI
President and Director
Sloan-Kettering Institute for Cancer Research
444 East 68th Street
New York, New York 10021

Dr. Robert O. Johnson - Guest
University of Wisconsin
Madison, Wisconsin

Dr. F. T. Kenney - Guest
Oak Ridge National Laboratory
Oak Ridge, Tennessee

Dr. Edwin A. Miranda - Alternate, AACI
Associate Institute Director
Roswell Park Memorial Institute
666 Elm Street
Buffalo, New York 14203

Dr. Robert A. Moreton - Guest
Vice President for Professional and Public Affairs
The University of Texas M. D. Anderson Hospital and Tumor Institute
Houston, Texas 77025

Dr. Gerald P. Murphy - Guest
Roswell Park
Buffalo, New York

Dr. Harold P. Rusch, Director - Member, AACI
McArthur Laboratory for Cancer Research
University of Wisconsin
1300 University Avenue
Madison, Wisconsin 53706
Dr. John S. Spratt, Jr., Director - Member, AACI  
Ellis Fischel Cancer Hospital and Cancer Research Center  
Business Loop 70 and Garth Avenue  
Columbia, Missouri 65201

Dr. Timothy R. Talbot, Jr., Director - Member, AACI  
The Institute for Cancer Research  
7701 Burholme Avenue  
Fox Chase  
Philadelphia, Pennsylvania 19111

Dr. Bela Toth - Guest  
Eppley Institute  
University of Nebraska  
Omaha, Nebraska

Dr. Mosao Yoguyama - Guest  
The University of Texas  
M. D. Anderson Hospital and Tumor Institute  
Texas Medical Center  
Houston, Texas 77025

Dr. David A. Wood, Director - Member, AACI  
Cancer Research Institute  
University of California  
Medical Center  
San Francisco, California 94122
INVITATIONS SENT TO FOREIGN INSTITUTES
THOSE IN ATTENDANCE
AACI MEETING - MAY 25, 1970

Dr. N. M. Alexandrov
Institute of Oncology and Radiology
of Belorussian
Minsk U.S.S.R.

Prof. E. Lima Basto, President
Instituto Portugues Oncologia
Palmalva, Lisbon, Portugal

Dr. N. N. Blokhin
Institute of Experimental & Clinical Oncology
Academy of Medical Sciences
Kashirskoe Shosse 6
Moscow B-409 U.S.S.R.

Dr. Eduardo Caceres, Director
Instituto Nacional de Enfermedades Neoplasicas
Avenida Alfonso Ugarte 825
Lima, Peru

Dr. Octave Costachel
Bucharest Oncological Institute
Ministry of Health and Social Welfare
Boulevard 1 Mai No. 11
Bucharest, Romania

Dr. O. Costa-Mandry, Medical Director
I Gonzales Martinez Oncologic Hospital
Puerto Rico Medical Center
Box 1811
Hato Rey, Puerto Rico

Roger Daoust, Ph.D., Director
Montreal Cancer Institute
Notre-Dame Hospital
Montreal 133, Canada

Dr. Marcel Dargent
Centre Leon Berard
20, Rue Laennec
F. 69 Lyon 8, France

Prof. Dr. Herwig Hamperl
Pathologisches Institut der Universitat Bonn
53 Bonn-Venusberg, Germany

Dr. E. Hecker (Representing Prof. K. H. Bauer)
German Centre for Cancer Research
Berliner Strasse 23
D 69 Heidelberg, Germany
INVITATIONS TO FOREIGN INSTITUTES
AACI INFORMAL MEETING

Professor Sir Alexander Haddow
Institute of Cancer Research
Royal Cancer Hospital
University of London
Fulham Road
London, W. W. 3, United Kingdom

Dr. John Higginson, Director
International Agency for Research on
Cancer 16, Avenue Marechal Foch 69
Lyon, France

Dr. J. H. C. Ho
M. N. D. Institute of Radiology
Queen Elizabeth Hospital
Kowloon, Hong Kong

Dr. T. Ichikawa, Director
The First National Hospital of Tokyo
1, Toyamacho, Shinjuku-ku
Tokyo, Japan

Dr. H. Isliker, Director
Institut Suisse de Recherches
Experimentales sur le Cancer
Bugnon 21
1005 Lausanne, Switzerland

Dr. T. Koszarowski, Director
Curie Institute of Oncology
Warsaw, Poland

Dr. André Lawoff
Centre de Recherches sur la
Cellule Normale et Cancereuse
16, Avenue P. Vallant-Couturier
94 Villejuif, France

Prof. O. Muhlböck
Netherlands Institute for Cancer Research
Antoni Van Leeuwenhoek-Huis
Sarphatistraat 108
Amsterdam C, Netherlands

Prof. A. L. Nasr
Cancer Institute, Faculty of Medicine
University of Cairo
Kasr el - Aini St set
Cairo, U. A. R. Egypt

Dr. Erik Poppe
The Norwegian Radium Hospital
Montebello - Oslo 3, Norway
INVITATIONS TO FOREIGN INSTITUTES
AACI INFORMAL MEETING

Dr. A. I. Rakov
M. M. Petrov's Institute of Oncology
U. S. S. R. Ministry of Health
Leningrad, U.S.S.R.

Dr. Dennis V. Rasis
Cancer Institute of Piraeus
Piraeus, Greece

Dr. Ivan Rode
National Cancer Institute
Hungary, Budapest

Dr. A. I. Saenko
Institute of Oncology of the Ministry
of Health of Kirgizian
Frunze, U.S.S.R.

Prof. C. G. Schmidt, President
Deutscher Zentralausschuss fur
Krebsbekampfung und Krebsforschung e. V
Hufelandstrasse 55, Klinikum
43 Essen, Germany

Prof. Ercole Sega (Representing Dr. A. Caputo)
Institute Regina Elena per lo Studio
e la Cura dei Tumori
Rome, Italy

Dr. Ivan T. Shevchenk
Institute of Oncology & Radiology
of the Ministry of Health of
Ukrainian S.S.R.
Kiev, U.S.S.R.

Prof. M. G. P. Stoker, Director
Imperial Cancer Research Fund
Lincoln's Inn Fields
London, W C 2, England

Dr. Robert Taylor
Secretary-General UICC
National Cancer Institute of Canada
25 Adelaide Street, East
Toronto 1, Ontario, Canada

Dr. Antonio Pinto Vieria
National Cancer Institute
Praça Cruz Vermelha 23
Rio de Janeiro, Guanabara, Brazil

Dr. Wilhelm Widow
Institute of Cancer Research of
Deutsche Akademie der Wissenschaften
East Berlin
Dr. T. Yoshida, Director
Cancer Institute
Japanese Foundation for Cancer Research
2615, Nishigagamo 2-chome, Toshima-ku
Tokyo, Japan

Dr. Michel Vandeputte
General Secretary
European Association for Cancer Research
First Congress
Brussels, Belgium

Dr. M. Gaitan Yanguas
Director, Instituto Nacional de Cancerologia
Bogota, Columbia

Dr. Dragicenc Veong
Tumor Institute
Zagreb, Yugoslavia

Representing Dr. Ivo Padovon, Tumor Institute
Zagreb, Yugoslavia

Dr. Maricic Zeljko
Tumor Institute
Zagreb, Yugoslavia
MAY 25, 1970
INFORMAL MEETING

MEMBERS AND ALTERNATES
ASSOCIATION OF AMERICAN CANCER INSTITUTES

(Not Present)

Dr. Howard Bodily
State Department of Public Health
Bureau of Chronic Diseases
2151 Berkeley Way
Berkeley, California 94704

Dr. Baruch S. Blumberg - Alternate
Associate Director for Clinical Research
The Institute for Cancer Research
7701 Burholme Avenue
Fox Chase
Philadelphia, Pennsylvania 19111

Dr. George E. Foley - Alternate
Associate Director for Laboratories
The Children's Cancer Research Foundation, Inc.
35 Binney Street
Boston, Massachusetts 02115

Dr. Alfred Cellhorn, Dean
The School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania 19104

Dr. Alexandre Gottschalk, Director
Argonne Cancer Research Hospital
950 E. 59th Street
Chicago, Illinois 60637

Dr. James T. Grace, Jr., Director
Roswell Park Memorial Institute
666 Elm Street
Buffalo, New York 14203

Dr. Paul J. Grotzinger, Medical Director
The American Oncologic Hospital
Central and Shelmire Avenues
Fox Chase
Philadelphia, Pennsylvania 19111

Dr. Francis T. Kenney - Alternate
Biomedical and Environmental Sciences
Oak Ridge National Laboratory
Post Office Box X
Oak Ridge, Tennessee 37830

Dr. Alfred G. Knudson
Associate Director (Education)
The University of Texas M. D. Anderson Hospital and Tumor Institute
Texas Medical Center
Houston, Texas
Dr. Henry M. Lemon
Division of Oncology
Department of Internal Medicine
University of Nebraska, Medical Center
Omaha, Nebraska

Dr. James L. Liverman
Associate Director
Biomedical and Environmental Sciences
Oak Ridge National Laboratory
Post Office Box X
Oak Ridge, Tennessee 37830

Dr. Bayard H. Morrison, III - Alternate
Assistant Director
National Cancer Institute
National Institutes of Health
Bethesda, Maryland 20014

Dr. George Nichols, Jr. (Dr. Shields Warren was to represent him)
Cancer Research Institute
New England Deaconess Hospital
185 Pilgrim Road
Boston, Massachusetts 02215

Dr. Albert H. Owens, Jr.
Professor of Medicine
Department of Medicine
Oncology Division
The Johns Hopkins Hospital
Baltimore, Maryland 21205

Dr. Bradford Patterson
Cancer Training Program (Invitation extended by Dr. Shields Warren)
New England Deaconess Hospital, 194 Pilgrim Road
Boston, Massachusetts 02215

Mr. Robert D. Pence, Business Manager - Alternate
Cancer Research Institute
New England Deaconess Hospital
185 Pilgrim Road
Boston, Massachusetts 02215

Dr. Donald P. Pinkel, Medical Director
St. Jude Children's Research Hospital
332 N. Lauderdale Street, P. O. Box 318
Memphis, Tennessee 38101

Dr. John Rowbotham, Medical Director (Invocation extended by Dr. Shields Warren)
Stoma Rehabilitation Clinic
New England Deaconess Hospital
194 Pilgrim Road
Boston, Massachusetts 02215
Mr. Howard Schurr - Alternate  
Fels Research Institute  
Temple University  
Health Sciences Center  
School of Medicine  
Philadelphia, Pennsylvania 19140

Dr. Philippe Shubik, Director  
The Eppley Institute for Research in Cancer  
University of Nebraska Medical Center  
42nd and Dewey Avenue  
Omaha, Nebraska 68105

Dr. William L. Simpson, Scientific Director  
Detroit Institute of Cancer Research  
4811 John R. Street  
Detroit, Michigan 48201

Dr. Howard E. Skipper  
Vice President and Director  
Kettering-Meyer Laboratories  
Southern Research Institute  
2000 Ninth Avenue South  
Birmingham, Alabama 35205

Dr. Leo Wade - Alternate  
Vice President and Deputy Director  
Sloan-Kettering Institute for Cancer Research  
444 East 68th Street  
New York, New York 10021

Dr. Shields Warren (Was to represent Dr. George Nichols, Jr.)  
Cancer Research Institute  
New England Deaconess Hospital  
194 Pilgrim Road  
Boston, Massachusetts 02215

Dr. Sidney Weinhouse, Director  
Fels Research Institute  
Temple University  
Health Sciences Center  
School of Medicine  
Philadelphia, Pennsylvania 19140

Dr. John E. Ulmann - Alternate  
Director of Clinical Oncology  
Argonne Cancer Research Hospital  
950 E. 59th Street  
Chicago, Illinois 60637
INVITATIONS SENT TO FOREIGN INSTITUTES
AACI MEETING - MAY 25, 1970
HOUSTON, TEXAS

(Not Present)

Dr. Petur Stoynev Andonov
Head, Department of Virology
Scientific Research Institute on
Epidemiology and Microbiology
Sofia, Bulgaria

Dr. Flavio Andrade M.
Instituto de Cancerología de Guatemala
6a Avenida 6-58 Zona 11
Guatemala City, Guatemala

Prof. Enrico Anglesio
Instituto Di Oncologia
Dell'Ospedale Di S. Giovanni
E Della Città Di Torino
Via. Cavour, 31 Torino, Italy

Dr. Enrique Barajas-Vallejo, Director
Instituto Nacional de Cancerolog ía
Av. Niños Héros 151
México 7, D.F. México

Dr. Karl-Heinrich Bauer, Director (Represented by Dr. E. Hecker)
Deutsches Krebsforschungszentrum
Berlinerstrasse 27
69, Heidelberg 1 Germany

Dr. I. Berenblum, Director (Was to be represented by Dr. N. Trainin)
Dept. Experimental Biology
The Weizmann Institute of Science
Rehovoth, Israel

Dr. J. Bernard
Institut de Recherches sur les Maldies
du Sang et les Leucémies
Faculte de Medecine de Paris
Hospital Saint-Louis
2, place du Dr. Fournier
F 75 Paris 10, France

Dr. E. H. Betz
Centre anticancereux
Universite de Liege
1, rue des Bonnes Villes
Liege, Belgium

Dr. J. Bichel
Cancer Research Institute in Collaboration with the Cancer Clinic
Radiumstationen
Aarhus, Denmark
Dr. R. G. Bourne, Senior Radiologist
The Queensland Radium Institute
Brisbane, Australia

Dr. Zbynek Brada
Cancer Research Institute
Zluty Kopec 7
Brno, Czechoslovakia

Prof. P. Bucalossi, Director (To be represented by Prof. U. Veronesi)
Instituto Nazionale per lo
Studie e la Cura dei Tumori
Piazzale Gorini 22, Milano, Italy

Prof. A. Caputo (Represented by Prof. Ercole Sega)
Regina Elena Cancer Institute
Viale Regina Elena
Rome, Italy

Dr. P. Carda
Instituto Nacional de Oncologia
Dirección General de Sanidad
Ciudad Universitaria
Madrid 3, Spain

Dr. Oliver Chance
St. Luke's Hospital
Highfield Road
Dublin, Ireland

A. Claude, Director (Dr. H. Tagnon was to represent)
Institut Jules Bordet
rue Heger Bordet 1
Brussels, Belgium

Dr. Luis Delclos
Hospital General de Asturias
Oviedo Asturias, Spain

Dr. Jorge de Marsilac, Director
Cancer Hospital
Rio de Janeiro, Brazil

Prof. Pierre Denoix, Directeur
Institut Gustave Roussy
16 bis, Avenue P. Vaillant-Couturier
94 Villejuif France

Dr. Giovanni D'Errico, Director
Istituto dei Tumori
Fondation Pascale
Cappella dei Cangiani
Naples, Italy
Dr. E. C. Easson
Director of Radiotherapy
Christie Hospital & Holt Radium Institute
Withington, Manchester 20 England

Dr. M. El Kharadly
Medical Research Institute
P.O.B. El Madara, Alexandria, U A R

Dr. Ennuyer
Fondation Curie
26, rue d'Ulm
F75, Paris 5, France

Dr. A. M. Evans (Dr. David A. Boyes was to represent him)
British Columbia Cancer Institute
2656 Heather Street
Vancouver 9, British Columbia

Dr. Manuel N. Fernández
Clínica Puerta de Hierro
Centro Nacional de Investigacion
Médico Quirúrgicas de la Seguridad Social
San Martín de Porres 4
Madrid 20, Spain

Dr. P. Foltz
Institut d'Oncologie
Hospital San Giovanni
Turin, Italy

Dr. Fernando Gentil
Institut Central, Hospital A. C. Camargo
Boîte Postale 5171
São Paulo, S. P. Brazil

Dr. R. M. Gonzalez
Hospital de Oncología
National Medical Center
Mexican Social Security Institute
México, D. F.

Dr. J. Guelfi
Centre regional de Lutte contre le Cancer
6, rue du Chapitre
F 35 Rennes, France

A. Habibi, Director
Tadj Pahlavi Cancer Institute
P. O. Box 14/1154
Tehran, Iran
Dr. Kiyoshi Hiraki (Dr. Tatsuo Sezaki was to represent him)
Director of University Hospital
Institute for Cancer Research
Okayama University Medical School
164 Oka
Okayama, Japan

Dr. Tamaki Imai, Director
Cancer Research Institute
Faculty of Medicine, Kyushu University
1276 Katakasu
Fukuoka, Japan

A. Ishizaki
Cancer Research Institute
Kanazawa University, 13-1
Takaramachi, Kanazawa, Japan

Dr. H. E. Johns
Division of Physics Research
Ontario Cancer Institute
500 Sherbourne Street
Toronto 5, Canada

Dr. Toshitaka Kanemoto
Head, Department of Gynecology
National Sapporo Hospital and Cancer Center
Hokkaido, Sapporo, Japan

Dr. Borijov Keil
Head, Department of Chemistry of Proteins
Institute of Organic Chemistry and Biochemistry
Czechoslovak Academy of Sciences, Prague
Czechoslovakia

Dr. B. Kellner
Research Institute of Oncopathology
Ministry of Health
Rath Gyorgy-Utca 5
Budapest 12, Hungary

Dr. H. Kolodziejska
Instytut Onkologii
Krakow, Poland
Dr. H. L. Kottmeier
Karolinska Institutet
Stockholm 60, Sweden

Dr. H. Kramer, Director
The Institute of Clinical Pathology and Medical Research
P. O. Box 108
Lidcombe, New South Wales, Australia

Dr. Toshio Kurokawa, President
Cancer Society of Miyagi Prefecture
7 Kita-7-bancho
Sendai, Japan

Dr. G. R. Kurrle, Medical Director
Cancer Institute
University of Melbourne
278 William Street
Melbourne, Australia

Dr. Masaru Kuru
National Cancer Center Hospital
Ministry of Health and Welfare
Tsukiji 5-chome, Chuo-ku
Tokyo, Japan

Dr. H. Maisin
Institut du Cancer
37, Voer des Capucins
Louvain
Belgium

Dr. Rafael Martinez, Director
Hospital de Oncologia
Centro Medico Nacional IMSS
Avenida Central 17
Mexico 7, D.F.

Dr. Georges Mathe, Directeur
Institut de Cancerologie et d'Immunogenetique
Hopital Paul-Brousse
14, Avenue P. Vaillant-Couturier
94 Villejuif, France

Dr. P. B. Medawar
National Institute for Medical Research
Mill Hill
London N.W. 7, United Kingdom England
Dr. Juan Jacobo Munoz, President (Dr. M. Gaitan Yanguas, Director attended)
National Cancer Institute
Calle 1 a No. 9-85
Bogota, Colombia

Dr. J. F. Murray
South African Institute for Medical Research
P. O. Box 1038
Johannesburg, So. Africa

Prof. Dr. Domingo Musto, Director (Dr. D. L. Perrazzo was to represent him)
Instituto de Oncologia "Angel H. Roffo"
Universidad de Buenos Aires
Av. San Martin 5481
Buenos Aires, Republica Argentina

Dr. W. Nakahara, Director
National Cancer Center
Research Institute
Ministry of Health and Welfare
Tsukiji 5-chome, chuo-ku
Tokyo, Japan

Dr. P. Nilprabhasorn
Cancer Institute
Sririraj Hospital
Bangkok, Thailand

Dr. Al. Oliveras-Guerra, Director (deceased)
I Gonzalez Martinez Oncologic Hospital
Puerto Rico Medical Center
Box 1811
Hato Rey, Puerto Rico

Dr. Kunio Oota, President
The Japanese Association for Cancer Research
c/o Cancer Institute
Nishisugamo, 2-chome
Toshima-ku, Tokyo, Japan

Dr. Ivo Padovan (Represented by Drs. Dragicenc Veong and Maricic Zeljko)
Tumor Institute
Zagreb, Yugoslavia

Dr. Ruben Pareja F.
Instituto Cancerologica "Cupertino Arteaga"
Casilla Correo No. 274
Sucre-Bolivia

Dr. J. C. Paymaster
Tata-Memorial Hospital
Government of India
Hospital Avenue
Parel, Bombay 12, India
Dr. D. L. Ferrazza (Was to represent Prof. Dr. Domingo Mosto)
Instituto de Oncologia "Angel H. Roffo"
Buenos Aires of U. of B.A.

Prof. H. Rahmatian
Cancer Institute of Iran
Pahlavi Hospital Cancer Research Dept.
Tehran, Iran

Dr. K. J. Ranaside
Cancer Research Institute
Tata-Memorial Centre
Hospital Avenue
Parel, Bombay 12, India

Dr. E. Ravento, Director
Fundacion Lopez Perez
Av. del Salvador 562
Santiago, Chile

Prof. M. Rivero,
Instituto del Cancer del Paraguay
Av. Peru y Juan de Salazar
Asunción, Paraguay

Dr. E. Saxen
Finish Cancer Registry
Cancer Society of Finland
Liisankatu 21
Helsinkf, Finland

Dr. F. Schmidt
Research Institute for Experimental Oncology
German Academy of Sciences
Alice-Bloch-Strasse 16
Potsdam-Rehbrucke, East Germany

Dr. Jerzy Jan Staszewski
Institute of Oncology, Biometry & Radiotherapy
Warsaw, Poland

Dr. T. Symington
Director of Chester Beatty Research Institute
London, England

Prof. H. Tagnon (Was to represent Dr. A. Claude)
Institut Jules Bordet
rue Heger Bordet
Brussels, Belgium
Dr. Ken'ichi Takeda, Director
Shinogi Research Laboratory
Shinogi & Co., Ltd.
Fukushima-ku
Osaka, Japan

Prof. M. D. Albertas Telichenas, Director
Institute of Oncology
Vilnius, Bokshto str. 6, U.S.S.R.
Lithuanian S.S.R.

Dr. William Thurzo, Director
Research Institute of Oncology
Bratislava, Czechoslovakia

Dr. J. E. Till
Head, Division of Biological Research
Ontario Cancer Institute
500 Sherbourne Street
Toronto 5, Canada

Dr. N. Trainin (To be represented by Dr. I. Berenblum)
The Weizmann Institute of Science
Rehovoth, Israel

Director, University of Chile
Institute of Biology
Cassilla 2988
Santiago, Chile

Dr. Ysidro Valladares, Head
Laboratory of Biology and Biochemistry of Cancer
Instituto Nacional de Oncologia
Ciudad Universitaria
Madrid 3, Spain

Prof. U. Veronesi
Instituto Nazionale per lo Studio e la Cura dei Tumori
Milano, Italy

Dr. Rene U. Villarreal
Hospital San Jose de Monterrey, S.A.
Apartado Postal No. 2830
Ave. Independencia Pte. No. 3000
Monterrey, N.L., Mexico

Dr. C. Zuckermann
Instituto Nacional de Cancerología
Avenida Niños Héroes 151
Mexico 7, D.F.
Mr. Lynn Baldwin  
Medical Communications  
May 13, 1970  
Dr. Robert C. Hickey

Dear Mr. Baldwin:

A meeting of various cancer institute directors—worldwide—will be held in the Research Medical Library on Monday, May 25th at 5:30 p.m. This is being sponsored by the American Association of Cancer Institutes in conjunction with the Tenth International Cancer Congress.

I would appreciate your arranging for Mr. James Dean to be present at the meeting to take photographs.

Thank you.

Sincerely,

Robert C. Hickey, M.D.

cc: Dr. R. Lee Clark
    Dr. Murray M. Copeland
Dear Bob:

I want you to know how grateful I am for all the excellent arrangements you made for the informal meeting and the reception sponsored by the Association of American Cancer Institutes when we were together in Houston at the Xth International Cancer Congress.

It seemed to me evident that many of our invited guests from abroad were much interested in the Association. I suspect it is likely that comparable associations may be developed, especially among European countries.

It was most kind of Mrs. Mickey and you to have had the large and most pleasant reception at your home. I know that all who were there enjoyed it as much as Norma and I did.

With warm personal regards,

Yours sincerely,

Frank L. Horsfall, Jr., M.D.
President
Association of American Cancer Institutes

Dr. Robert C. Mickey
Deputy Director
M.D. Anderson Hospital and Tumor Institute
The University of Texas
Texas Medical Center
Houston, Texas 77025

cc: Dr. R. Lee Clark
Dr. Edwin A. Mirand
Participants, American Association  
of Cancer Institutes Meeting  
May 25, 1970, Houston, Texas  

Gentlemen:

Enclosed herewith are several photographs taken at the  
meeting of the American Association of Cancer Institutes in  
Houston.

We hope you will enjoy them.

I believe all present felt this a memorable occasion.

The large group photograph lacks complete individual identifications. To avoid any error, we would appreciate it if you  
would identify yourself on the overlay attached to the photograph,  
and return your identification number to my office. We shall then  
mail the captions to each of you.

To the American Association of Cancer Institutes members, we  
appreciated your participation and to all guests--return!

Very truly yours,

Robert C. Hickey, M. D.  
Executive Vice President  
and Director

RCH/jw  
enclosure
MAY 25, 1970
AACI INFORMAL MEETING
MEMBERS AND ALTERNATES
and INVITED GUESTS
THOSE IN ATTENDANCE
ASSOCIATION OF AMERICAN CANCER INSTITUTES

Dr. Carl Baker, Acting Director - Member, AACI
National Cancer Institute
National Institutes of Health
Bethesda, Maryland 20014

Richard Ballard - guest
Oklahoma Medical Research Foundation
Oklahoma City
Oklahoma

Dr. Michael J. Brennan - Member, AACI
Medical and Scientific Director
The Michigan Cancer Foundation
4811 John R. Street
Detroit, Michigan 48201

Dr. Walter J. Burdette - Guest
Associate Director (Research)
M. D. Anderson Hospital and Tumor Institute
Texas Medical Center
Houston, Texas 77025

Dr. R. Lee Clark, President - Member, AACI
The University of Texas at Houston
M. D. Anderson Hospital and Tumor Institute
Texas Medical Center
Houston, Texas 77025

Dr. Paul T. Condit - Member, AACI
Head, Cancer Section
Oklahoma Medical Research Foundation
825 Northeast Thirteenth Street
Oklahoma City, Oklahoma 73104

Dr. Murray M. Copeland, Vice-President - Alternate, AACI
University Cancer Foundation
The University of Texas at Houston
M. D. Anderson Hospital and Tumor Institute
Houston, Texas 77025

Dr. A. R. Curreri, Chairman - Member, AACI
Department of Surgery
Director, Division of Clinical Oncology
University of Wisconsin Medical Center
1300 University Avenue
Madison, Wisconsin 53706
Dr. G. di Mayorca - Alternate, AACI
Eppley Institute for Research in Cancer
Omaha, Nebraska

Dr. Sidney Farber - Member, AACI
Director of Research
The Children's Cancer Research Foundation, Inc.
35 Binney St.
Boston, Massachusetts 02115

Dr. Robert C. Hickey - Alternate, AACI
Executive Vice President and Director
The University of Texas
M. D. Anderson Hospital and Tumor Institute
Texas Medical Center
Houston, Texas 77025

Dr. Frank L. Horsfall, Jr. - Member, AACI
President and Director
Sloan-Kettering Institute for Cancer Research
444 East 68th Street
New York, New York 10021

Dr. Robert O. Johnson - Guest
University of Wisconsin
Madison, Wisconsin

Dr. F. T. Kenney - Guest
Oak Ridge National Laboratory
Oak Ridge, Tennessee

Dr. Edwin A. Mirand - Alternate, AACI
Associate Institute Director
Roswell Park Memorial Institute
666 Elm Street
Buffalo, New York 14203

Dr. Robert A. Moreton - Guest
Vice President for Professional and Public Affairs
The University of Texas
M. D. Anderson Hospital and Tumor Institute
Houston, Texas 77025

Dr. Gerald P. Murphy - Guest
Roswell Park
Buffalo, New York

Dr. Harold P. Rusch, Director - Member, AACI
McArdle Laboratory for Cancer Research
University of Wisconsin
1300 University Avenue
Madison, Wisconsin 53706
Dr. John S. Spratt, Jr., Director - Member, AACI
Ellis Fishel Cancer Hospital and Cancer Research Center
Business Loop 70 and Garth Avenue
Columbia, Missouri 65201

Dr. Timothy R. Talbot, Jr., Director - Member, AACI
The Institute for Cancer Research
7701 Burholme Avenue
Fox Chase
Philadelphia, Pennsylvania 19111

Dr. Bela Toth - Guest
Eppley Institute
University of Nebraska
Omaha, Nebraska

Dr. Norao Yoguyama - Guest
The University of Texas
M. D. Anderson Hospital and Tumor Institute
Texas Medical Center
Houston, Texas 77025

Dr. David A. Wood, Director - Member, AACI
Cancer Research Institute
University of California
Medical Center
San Francisco, California 94122
INVITATIONS SENT TO FOREIGN INSTITUTES
THOSE IN ATTENDANCE
AACI MEETING - MAY 25, 1970

Dr. N. N. Alexandrov
Institute of Oncology and Radiology
of Belorussian
Minsk U.S.S.R.

Prof. E. Lima Basto, President
Instituto Português Oncologia
Palhava, Lisbon, Portugal

Dr. N. N. Blokhin
Institute of Experimental & Clinical Oncology
Academy of Medical Sciences
Kashirskoe Shosse 6
Moscow B-409 U.S.S.R.

Dr. Eduardo Caceres, Director
Instituto Nacional de Enfermedades Neoplasicas
Avenida Alfonso Ugarte 825
Lima, Peru

Dr. Octave Costachel
Bucharest Oncological Institute
Ministry of Health and Social Welfare
Boulevard 1 Mai No. 11
Bucharest, Romania

Dr. O. Costa-Mandry, Medical Director
I Gonzales Martinez Oncologic Hospital
Puerto Rico Medical Center
Box 1811
Hato Rey, Puerto Rico

Roger Daoust, Ph.D., Director
Montreal Cancer Institute
Notre-Dame Hospital
Montreal 133, Canada

Dr. Marcel Dargent
Centre Leon Berard
28, Rue Laennec
F. 69 Lyon 8, France

Prof. Dr. Herwig Hamperl
Pathologisches Institut der Universität Bonn
53 Bonn-Venusberg, Germany

Dr. E. Hecker (Representing Prof. K. H. Bauer)
German Centre for Cancer Research
Berliner Strasse 23
D 69 Heidelberg, Germany
INVITATIONS TO FOREIGN INSTITUTES
AACI INFORMAL MEETING

Professor Sir Alexander Haddow
Institute of Cancer Research
Royal Cancer Hospital
University of London
Fulham Road
London, W. W. 3, United Kingdom

Dr. John Higginson, Director
International Agency for Research on Cancer
16, Avenue Marechal Foch 69
Lyon, France

Dr. J. H. C. Ho
M. H. D. Institute of Radiology
Queen Elizabeth Hospital
Kowloon, Hong Kong

Dr. T. Ichikawa, Director
The First National Hospital of Tokyo
1, Toyamacho, Shinjuku-ku
Tokyo, Japan

Dr. H. Isliker, Director
Institut Suisse de Recherches Experimentales sur le Cancer
Bugnon 21
1005 Lausanne, Switzerland

Dr. T. Koszarowski, Director
Curie Institute of Oncology
Warsaw, Poland

Dr. André Lwoff
Centre de Recherches sur la Cellule Normale et Cancereuse
16, Avenue P. Vallant-Couturier
94 Villejuif, France

Prof. O. Muhlbock
Netherlands Institute for Cancer Research
Antoni Van Leeuwenhoek-Huis
Sarphatistraat 108
Amsterdam C, Netherlands

Prof. A. L. Nasr
Cancer Institute, Faculty of Medicine
University of Cairo
Kasr el - Aini Street
Cairo, U. A. R. Egypt

Dr. Erik Poppe
The Norwegian Radium Hospital
Montebello - Oslo 3, Norway
INVITATIONS TO FOREIGN INSTITUTES
AACI INFORMAL MEETING

Dr. A. I. Rakov
N. N. Petrov's Institute of Oncology
U. S. S. R. Ministry of Health
Leningrad, U.S.S.R.

Dr. Dennis V. Razis
Cancer Institute of Piraeus
Piraeus, Greece

Dr. Ivan Rode
National Cancer Institute
Hungary, Budapest

Dr. A. I. Saenko
Institute of Oncology of the Ministry
of Health of Kirgizian
Frunze, U.S.S.R.

Prof. C. G. Schmidt, President
Deutscher Zentralausschuss fur
Krebsbekampfung und Krebsforschung e. V
Hufelandstrasse 55, Klinikum
43 Essen, Germany

Prof. Ercole Sega (Representing Dr. A. Caputo)
Institute Regina Elena per lo Studio
e la Cura dei Tumori
Rome, Italy

Dr. Ivan T. Shevchenk
Institute of Oncology & Radiology
of the Ministry of Health of
Ukranian S.S.R.
Kiev, U.S.S.R.

Prof. M. G. P. Stoker, Director
Imperial Cancer Research Fund
Lincoln's Inn Fields
London, W C 2, England

Dr. Robert Taylor
Secretary-General UICC
National Cancer Institute of Canada
25 Adelaide Street, East
Toronto 1, Ontario, Canada

Dr. Antonio Pinto Vieria
National Cancer Institute
Praca Cruz Vermelha 23
Rio de Janeiro, Guanabara, Brazil

Dr. Wilhelm Widow
Institute of Cancer Research of
Deutsche Akademie der Wissenschaften
East Berlin
INVITATIONS TO FOREIGN INSTITUTES
AACI INFORMAL MEETING

Dr. T. Yoshida, Director
Cancer Institute
Japanese Foundation for Cancer Research
2615, Nishisugamo 2-chome, Toshima-ku
Tokyo, Japan

Dr. Michel Vandeputte
General Secretary
European Association for Cancer Research
First Congress
Brussels, Belgium

Dr. M. Gaitan Yanguas
Director, Instituto Nacional de Cancerologia
Bogota, Columbia

Dr. Dragicenc Veong
Tumor Institute
Zagreb, Yugoslavia

Dr. Maricic Zeljko
Tumor Institute
Zagreb, Yugoslavia

) Representing Dr. Ivo Padovon, Tumor Institute
Zagreb, Yugoslavia
MAY 25, 1970
INFORMAL MEETING

MEMBERS AND ALTERNATES
ASSOCIATION OF AMERICAN CANCER INSTITUTES

(Not Present)

Dr. Howard Bodily
State Department of Public Health
Bureau of Chronic Diseases
2151 Berkeley Way
Berkeley, California 94704

Dr. Baruch S. Blumberg - Alternate
Associate Director for Clinical Research
The Institute for Cancer Research
7701 Burholme Avenue
Fox Chase
Philadelphia, Pennsylvania 19111

Dr. George E. Foley - Alternate
Associate Director for Laboratories
The Children's Cancer Research Foundation, Inc.
35 Binney Street
Boston, Massachusetts 02115

Dr. Alfred Gellhorn, Dean
The School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania 19104

Dr. Alexandre Gottschalk, Director
Argonne Cancer Research Hospital
950 E. 59th Street
Chicago, Illinois 60637

Dr. James T. Grace, Jr., Director
Roswell Park Memorial Institute
666 Elm Street
Buffalo, New York 14203

Dr. Paul J. Grotzingcr, Medical Director
The American Oncologic Hospital
Central and Shelmire Avenues
Fox Chase
Philadelphia, Pennsylvania 19111

Dr. Francis T. Kenney - Alternate
Biomedical and Environmental Sciences
Oak Ridge National Laboratory
Post Office Box X
Oak Ridge, Tennessee 37830

Dr. Alfred G. Knudson
Associate Director (Education)
The University of Texas M. D. Anderson Hospital and Tumor Institute
Texas Medical Center
Houston, Texas
Dr. Henry M. Lemon
Division of Oncology
Department of Internal Medicine
University of Nebraska, Medical Center
Omaha, Nebraska

Dr. James L. Liverman
Associate Director
Biomedical and Environmental Sciences
Oak Ridge National Laboratory
Post Office Box X
Oak Ridge, Tennessee 37830

Dr. Bayard H. Morrison, III - Alternate
Assistant Director
National Cancer Institute
National Institutes of Health
Bethesda, Maryland 20014

Dr. George Nichols, Jr. (Dr. Shields Warren was to represent him)
Cancer Research Institute
New England Deaconess Hospital
185 Pilgrim Road
Boston, Massachusetts 02215

Dr. Albert H. Owens, Jr.
Professor of Medicine
Department of Medicine
Oncology Division
The Johns Hopkins Hospital
Baltimore, Maryland 21205

Dr. Bradford Patterson
Cancer Training Program (Invitation extended by Dr. Shields Warren)
New England Deaconess Hospital, 194 Pilgrim Road
Boston, Massachusetts 02215

Mr. Robert D. Pence, Business Manager - Alternate
Cancer Research Institute
New England Deaconess Hospital
185 Pilgrim Road
Boston, Massachusetts 02215

Dr. Donald P. Pinkel, Medical Director
St. Jude Children's Research Hospital
332 N. Lauderdale Street, P. O. Box 318
Memphis, Tennessee 38101

Dr. John Rowbotham, Medical Director (Invitation extended by Dr. Shields Warren)
Stoma Rehabilitation Clinic
New England Deaconess Hospital
194 Pilgrim Road
Boston, Massachusetts 02215
Mr. Howard Schurr - Alternate
Fels Research Institute
Temple University
Health Sciences Center
School of Medicine
Philadelphia, Pennsylvania 19140

Dr. Philippe Shubik, Director
The Eppley Institute for Research in Cancer
University of Nebraska Medical Center
42nd and Dewey Avenue
Omaha, Nebraska 68105

Dr. William L. Simpson, Scientific Director
Detroit Institute of Cancer Research
4811 John R. Street
Detroit, Michigan 48201

Dr. Howard E. Skipper
Vice President and Director
Kettering-Meyer Laboratories
Southern Research Institute
2000 Ninth Avenue South
Birmingham, Alabama 35205

Dr. Leo Wade - Alternate
Vice President and Deputy Director
Sloan-Kettering Institute for Cancer Research
444 East 68th Street
New York, New York 10021

Dr. Shields Warren (Was to represent Dr. George Nichols, Jr.)
Cancer Research Institute
New England Deaconess Hospital
194 Pilgrim Road
Boston, Massachusetts 02215

Dr. Sidney Weinhouse, Director
Fels Research Institute
Temple University
Health Sciences Center
School of Medicine
Philadelphia, Pennsylvania 19140

Dr. John E. Ultmann - Alternate
Director of Clinical Oncology
Argonne Cancer Research Hospital
950 E. 59th Street
Chicago, Illinois 60637
INVITATIONS SENT TO FOREIGN INSTITUTES
AACI MEETING - MAY 25, 1970
HOUSTON, TEXAS

(Not Present)

Dr. Petur Stoynov Andonov
Head, Department of Virology
Scientific Research Institute on
Epidemiology and Microbiology
Sofia, Bulgaria

Dr. Flavio Andrade M.
Instituto de Cancerología de Guatemala
6a Avenida 6-58 Zona 11
Guatemala City, Guatemala

Prof. Enrico Anglesio
Instituto Di Oncologia
Dell'Ospedale Di S. Giovanni
E Nella Città Di Torino
Via Cavour, 31 Torino, Italy

Dr. Enrique Barajas-Vallejo, Director
Instituto Nacional de Cancerología
Av. Niños Héroes 151
México 7, D.F. México

Dr. Karl-Heinrich Bauer, Director (Represented by Dr. E. Hecker)
Deutsches Krebsforschungszentrum
Berlinerstrasse 27
69, Heidelberg 1 Germany

Dr. I. Berenblum, Director (Was to be represented by Dr. N. Trainin)
Dept. Experimental Biology
The Weizmann Institute of Science
Rehovoth, Israel

Dr. J. Bernard
Institut de Recherches sur les Maladies
du Sang et les Leucémies
Faculte de Medecine de Paris
Hospital Saint-Louis
2, place du Dr. Fournier
F 75 Paris 10, France

Dr. E. H. Betz
Centre anticancereux
Universite de Liege
1, rue des Bonnes Villes
Liege, Belgium

Dr. J. Bichel
Cancer Research Institute in Collaboration with the Cancer Clinic
Radiumstationen
Aarhus, Denmark
Dr. R. G. Bourne, Senior Radiologist
The Queensland Radium Institute
Brisbane, Australia

Dr. Zbyněk Brada
Cancer Research Institute
Zluty Kopec 7
Brno, Czechoslovakia

Prof. P. Bucalossi, Director (To be represented by Prof. U. Veronesi)
Instituto Nazionale per lo Studie e la Cura dei Tumori
Piazzale Gorini 22, Milano, Italy

Prof. A. Caputo (Represented by Prof. Ercole Sega)
Regina Elena Cancer Institute
Viale Regina Elena
Rome, Italy

Dr. P. Carda
Instituto Nacional de Oncologia
Dirección General de Sanidad
Ciudad Universitaria
Madrid 3, Spain

Dr. Oliver Chance
St. Luke's Hospital
Highfield Road
Dublin, Ireland

A. Claude, Director (Dr. H. Tagnon was to represent)
Institut Jules Bordet
rue Heger Bordet 1
Brussels, Belgium

Dr. Luis Delclos
Hospital General de Asturias
Oviedo Asturias, Spain

Dr. Jorge de Marsilac, Director
Cancer Hospital
Rio de Janeiro, Brazil

Prof. Pierre Denoix, Directeur
Institut Gustave Roussy
16 bis, Avenue P. Vaillant-Couturier
94 Villejuif France

Dr. Giovanni D'Errico, Director
Instituto dei Tumori
Fondation Pascale
Cappella dei Cangiani
Naples, Italy
Dr. E. C. Easson
Director of Radiotherapy
Christie Hospital & Holt Radium Institute
Withington, Manchester 20 England

Dr. M. El Kharadly
Medical Research Institute
P.O.B. El Madara, Alexandria, U A R

Dr. Enmuyer
Fondation Curie
26, rue d’Ulm
F75, Paris 5, France

Dr. A. M. Evans (Dr. David A. Boyes was to represent him)
British Columbia Cancer Institute
2656 Heather Street
Vancouver 9, British Columbia

Dr. Manuel N. Fernández
Clinica Puerta de Hierro
Centro National de Investigacion
Médico Quirúrgicas de la Seguridad Social
San Martín de Porres 4
Madrid 20, Spain

Dr. P. Foltz
Institut d’Oncologie
Hospital San Giovanni
Turin, Italy

Dr. Fernando Gentil
Institut Central, Hospital A. C. Camargo
Boîte Postale 5171
São Paulo, S. P. Brazil

Dr. R. M. Gonzalez
Hospital de Oncología
National Medical Center
Mexican Social Security Institute
México, D. F.

Dr. J. Guelfi
Centre regional de Lutte contre le Cancer
6, rue du Chapitre
F.35 Rennes, France

A. Habibi, Director
Tadj Pahlavi Cancer Institute
P. O. Box 14/1154
Tehran, Iran
Dr. Kiyoshi Hiraki (Dr. Tatsuo Sezaki was to represent him)
Director of University Hospital
Institute for Cancer Research
Okayama University Medical School
164 Oka
Okayama, Japan

Dr. Tamaki Imai, Director
Cancer Research Institute
Faculty of Medicine, Kyushu University
1276 Katakasu
Fukuoka, Japan

A. Ishizaki
Cancer Research Institute
Kanazawa University, 13-1
Takaramachi, Kanazawa, Japan

Dr. H. E. Johns
Division of Physics Research
Ontario Cancer Institute
500 Sherbourne Street
Toronto 5, Canada

Dr. Toshitaka Kanemoto
Head, Department of Gynecology
National Sapporo Hospital and Cancer Center
Hokkaido, Sapporo, Japan

Dr. Borijov Keil
Head, Department of Chemistry of Proteins
Institute of Organic Chemistry and Biochemistry
Czechoslovak Academy of Sciences, Prague
Czechoslovakia

Dr. B. Kellner
Research Institute of Oncopathology
Ministry of Health
Rath Gyorgy-Utca 5
Budapest 12, Hungary

Dr. H. Kolodziejska
Instytut Onkologii
Krakow, Poland
Dr. H. L. Kothmeier  
Karolinska Institutet  
Stockholm 60, Sweden

Dr. H. Kramer, Director  
The Institute of Clinical Pathology and Medical Research  
P. O. Box 108  
Lidcombe, New South Wales, Australia

Dr. Toshio Kurokawa, President  
Cancer Society of Miyagi Prefecture  
7 Kita-7-bancho  
Sendai, Japan

Dr. G. R. Kurrle, Medical Director  
Cancer Institute  
University of Melbourne  
278 William Street  
Melbourne, Australia

Dr. Masaru Kuru  
National Cancer Center Hospital  
Ministry of Health and Welfare  
Tsukiji 5-chome, Chuo-ku  
Tokyo, Japan

Dr. H. Maisin  
Institut du Cancer  
37, Voer des Capucins  
Louvain  
Belgium

Dr. Rafael Martinez, Director  
Hospital de Oncologia  
Centro Medico Nacional IMSS  
Avenida Central 17  
Mexico 7, D.F.

Dr. Georges Nathe, Directeur  
Institut de Cancerologie et  
d'Immunogenetique  
Hopital Paul-Brousse  
14, Avenue P. Vaillant-Couturier  
94 Villejuif, France

Dr. P. B. Medawar  
National Institute for Medical Research  
Mill Hill  
London N.W. 7, United Kingdom England
Dr. Juan Jacobo Munoz, President  (Dr. M. Galton Yangun, Director attended)
National Cancer Institute
Calle 1 a No. 9-85
Bogota, Colombia

Dr. J. F. Murray
South African Institute for Medical Research
P. O. Box 1038
Johannesburg, So. Africa

Prof. Dr. Domingo Musto, Director (Dr. D. L. Ferrazzio was to represent him)
Instituto de Oncologia "Angel H. Roffo"
Universidad de Buenos Aires
Av. San Martin 5481
Buenos Aires, Republica Argentina

Dr. W. Nakahara, Director
National Cancer Center
Research Institute
Ministry of Health and Welfare
Tsukiji 5-chome, chuo-ku
Tokyo, Japan

Dr. P. Nilprabhasorn
Cancer Institute
Siriraj Hospital
Bangkok, Thailand

Dr. A1. Oliveras-Guerra, Director (deceased)
I Gonzalez Martinez Oncologic Hospital
Puerto Rico Medical Center
Box 1811
Hato Rey, Puerto Rico

Dr. Kunio Oota, President
The Japanese Association for Cancer Research
c/o Cancer Institute
Nishisugamo, 2-chome
Toshima-ku, Tokyo, Japan

Dr. Ivo Padovan (Represented by Drs. Dragicen Veong and Maricic Zeljko)
Tumor Institute
Zagreb, Yugoslavia

Dr. Ruben Pareja F.
Instituto Cancerologio "Cupertino Arteaga"
Casilla Correo No. 274
Sucre-Bolivia

Dr. J. C. Paymaster
Tata-Memorial Hospital
Government of India
Hospital Avenue
Parel, Bombay 12, India
Dr. D. L. Perrazzo (Was to represent Prof. Dr. Domingo Musto)  
Instituto de Oncologia "Angel H. Roffo"  
Buenos Aires of U. of B.A.

Prof. H. Rahmatian  
Cancer Institute of Iran  
Pahlavi Hospital Cancer Research Dept.  
Tehran, Iran

Dr. K. J. Ranadive  
Cancer Research Institute  
Tata-Memorial Centre  
Hospital Avenue  
Parel, Bombay 12, India

Dr. E. Raventos, Director  
Fundacion Lopez Perez  
Av. del Salvador 562  
Santiago, Chile

Prof. M. Riveros  
Instituto del Cancer del Paraguay  
Av. Peru y Juan de Salazar  
Asuncion, Paraguay

Dr. E. Saxen  
Finnish Cancer Registry  
Cancer Society of Finland  
Liisankatu 21  
Helsinki, Finland

Director  
University of Chile School of Medicine  
Department of Oncology  
Santiago, Chile

Dr. F. Schmidt  
Research Institute for Experimental Oncology  
German Academy of Sciences  
Alice-Bloch-Strasse 16  
Potsdam-Rehbrucke, East Germany

Dr. Jerzy Jan Staszewski  
Institute of Oncology, Biometry & Radiotherapy  
Warsaw, Poland

Dr. T. Symington  
Director of Chester Beatty Research Institute  
London, England

Prof. H. Tagnon (Was to represent Dr. A. Claude)  
Institut Jules Bordet  
rue Heger Bordet  
Brussels, Belgium
Dr. Ken'ichi Takeda, Director
Shinogi Research Laboratory
Shinogi & Co., Ltd.
Fukushima-ku
Osaka, Japan

Prof. M. D. Albertas Telichenas, Director
Institute of Oncology
Vilnius, Bokshto str. 6, U.S.S.R.,
Lithuanian S.S.R.

Dr. Villiam Thurzo, Director
Research Institute of Oncology
Bratislava, Czechoslovakia

Dr. J. E. Till
Head, Division of Biological Research
Ontario Cancer Institute
500 Sherbourne Street
Toronto 5, Canada

Dr. N. Trainin (To be represented by Dr. I. Berenblum)
The Weizmann Institute of Science
Rehovoth, Israel

Director, University of Chile
Institute of Biology
Cassilla 2988
Santiago, Chile

Dr. Ysidro Valladares, Head
Laboratory of Biology and Biochemistry of Cancer
Instituto Nacional de Oncologia
Ciudad Universitaria
Madrid 3, Spain

Prof. U. Veronesi
Instituto Nazionale per lo Studio e la Cura dei Tumori
Milano, Italy

Dr. Rene U. Villarreal
Hospital San Jose de Monterrey, S.A.
Apartado Postal No. 2830
Ave. Independencia Pte. No. 3000
Monterrey, N.L., Mexico

Dr. C. Zuckermann
Instituto Nacional de Cancerología
Avenida Niños Héroes 151
Mexico 7, D.F.
<table>
<thead>
<tr>
<th>Name</th>
<th>Institute</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prof. Alexandrov</td>
<td>Oncol. Inst.</td>
<td>USSR</td>
</tr>
<tr>
<td>Robert A. Johnson</td>
<td>Univ. of Wisconsin</td>
<td>USA</td>
</tr>
<tr>
<td>Oskar Gelfries</td>
<td>Tumor Klinik (University of Essen)</td>
<td>Germany</td>
</tr>
<tr>
<td>T. R. Albrecht</td>
<td>IRC, Philadelphia</td>
<td>PA</td>
</tr>
<tr>
<td>Koszarowski</td>
<td>Curie Institute of Oncology</td>
<td>Poland</td>
</tr>
<tr>
<td>John Spinelli</td>
<td>Ellis Fischel Cancer Hosp. &amp; Res. Ctr.</td>
<td>Columbia, NY, USA</td>
</tr>
<tr>
<td>Eric Hecker</td>
<td>German Cancer Res. Center</td>
<td>Germany</td>
</tr>
<tr>
<td>R. D. Rotterdam</td>
<td>Children's Med Res. Found.</td>
<td>EHL, CA, USA</td>
</tr>
<tr>
<td>J. F. Murphy</td>
<td>Roswell Park</td>
<td>USA</td>
</tr>
<tr>
<td>H. Kansy</td>
<td>Lewis BMH, Germany</td>
<td>Germany</td>
</tr>
<tr>
<td>Michael J. Brennan</td>
<td>Detroit, USA</td>
<td>USA</td>
</tr>
<tr>
<td>Main Galvani</td>
<td>National Cancer Inst. Bogota, Italy</td>
<td></td>
</tr>
<tr>
<td>Masan Yeshiyama</td>
<td>M.D. Anderson Hosp. &amp; Res. Inst.</td>
<td>USA</td>
</tr>
<tr>
<td>John H. Y. Ho</td>
<td>Hong Kong Queen Elizabeth, Hosp.</td>
<td></td>
</tr>
<tr>
<td>Daniel T. Kennedy</td>
<td>Oak Ridge National Laboratory</td>
<td>USA</td>
</tr>
<tr>
<td>Harold P. Distel</td>
<td>Medische Faculteit, Univ. of Wis.</td>
<td>USA</td>
</tr>
<tr>
<td>Otto van Boeijen</td>
<td>Netherlands Cancer Inst. Amersfoort</td>
<td></td>
</tr>
<tr>
<td>Bela Toth</td>
<td>Eppey Inst. Univ. of Nebraska, Omaha, NE, USA</td>
<td></td>
</tr>
<tr>
<td>Eduardo Caceres</td>
<td>Instituto Nacional de Enfermedades</td>
<td>LIMA, PERU</td>
</tr>
<tr>
<td>Neo Plasticas</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Michel Vanden Putte</td>
<td>Rega Institute, Leuven, Belgium</td>
<td></td>
</tr>
<tr>
<td>P. J. Smith</td>
<td>Oklahoma Med. Sch. Inst.</td>
<td>USA</td>
</tr>
<tr>
<td>Name</td>
<td>Institute</td>
<td>Country</td>
</tr>
<tr>
<td>-----------------------</td>
<td>------------------------------------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Erik Poppe</td>
<td>Norwegian Radium Hospital, Oslo</td>
<td>Norway</td>
</tr>
<tr>
<td>Costache Octavie</td>
<td>Bucharest, Oncological Institute</td>
<td>Romania</td>
</tr>
<tr>
<td>Dennis V. Razi</td>
<td>Cancer Institute of Piraeus, Piraeus, Greece</td>
<td></td>
</tr>
<tr>
<td>Stepanov J.</td>
<td>Higher Institute of Oncology, USSR</td>
<td></td>
</tr>
<tr>
<td>Robert D. Morton</td>
<td>M.D. Anderson, Houston, Texas</td>
<td></td>
</tr>
<tr>
<td>John Haynes</td>
<td>IARC, Lyon, France</td>
<td></td>
</tr>
<tr>
<td>Tomizo Yoshida</td>
<td>Cancer Institute, Tokyo</td>
<td>Japan</td>
</tr>
<tr>
<td>Tohji Ichikawa</td>
<td>The First National Hospital of Tokyo</td>
<td>Japan</td>
</tr>
<tr>
<td>Roger Dumont, PhD</td>
<td>Montreal Cancer Institute, Montreal, Canada</td>
<td></td>
</tr>
<tr>
<td>Vedran Majicic, M.D.</td>
<td>Tumor Institute, Zagreb, Yugoslavia</td>
<td></td>
</tr>
<tr>
<td>Dr. Zeljko Maticic</td>
<td>Tumor Institute, Zagreb, Yugoslavia</td>
<td></td>
</tr>
<tr>
<td>E. Lima Basto</td>
<td>Instituto Portugueses Oncologicos, Lisbon</td>
<td>Portugal</td>
</tr>
<tr>
<td>W. Steiner</td>
<td>Inst. Cancer Research and Lending</td>
<td></td>
</tr>
<tr>
<td>H. Seiler</td>
<td>Switzerland, Lausanne</td>
<td></td>
</tr>
<tr>
<td>L. Winer</td>
<td>Robert-Kohls Klinik, Buch, GDR</td>
<td></td>
</tr>
<tr>
<td>A. Bahri Alastor</td>
<td>Cancer Institute, Cairo</td>
<td></td>
</tr>
<tr>
<td>J. Schmidheiny</td>
<td>Instituto Nacional Cancer Research, Mexico</td>
<td></td>
</tr>
<tr>
<td>J. Fleiss, J. Fleiss</td>
<td>Children's Cancer Research Foundation, Boston</td>
<td></td>
</tr>
<tr>
<td>Uriben G. Marcal</td>
<td>Roswell Park, Jr., Memorial Institute</td>
<td></td>
</tr>
<tr>
<td>J. Rode, K.H.</td>
<td>National Cancer Inst., N. Hungary</td>
<td></td>
</tr>
<tr>
<td>Prof. E. Hickey</td>
<td>N.D. Anderson, USA</td>
<td></td>
</tr>
<tr>
<td>Carl H. Bamber</td>
<td>NCI, NIH, USA</td>
<td></td>
</tr>
<tr>
<td>Sherchenko (Kiev)</td>
<td>USSR</td>
<td></td>
</tr>
<tr>
<td>N. Blokhin</td>
<td>Moscow, USSR</td>
<td></td>
</tr>
<tr>
<td>R. Guschin</td>
<td>Moscow, USSR</td>
<td></td>
</tr>
<tr>
<td>M. Khachan</td>
<td>Evgeny Medu, Moscow, USSR</td>
<td></td>
</tr>
<tr>
<td>J. M. Jones</td>
<td>Effray, Cancer Inst., Ontario, NEB</td>
<td></td>
</tr>
<tr>
<td>J. A. A. Laufkof</td>
<td>Pasteur Inst., Paris</td>
<td></td>
</tr>
<tr>
<td>NAME</td>
<td>INSTITUTE</td>
<td>COUNTRY</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------------------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Frank Mitchell</td>
<td>St. John's Medical Centre</td>
<td>USA</td>
</tr>
<tr>
<td>Hilda Mack</td>
<td>Royal London Hospital</td>
<td>Ontario, Canada</td>
</tr>
<tr>
<td>E. Gumeli</td>
<td>21st of July Center</td>
<td>U.S.A.</td>
</tr>
<tr>
<td>Ilia Sepo</td>
<td>Royal Genoa Cancer Institute</td>
<td>Rome, Italy</td>
</tr>
<tr>
<td>Dargent</td>
<td>Centre leonard jadis</td>
<td>France</td>
</tr>
<tr>
<td>R. Kev A.</td>
<td>Institute of Oncology</td>
<td>London, UK</td>
</tr>
<tr>
<td>R. Lee Clark</td>
<td>M.D. Anderson Hospital T.I.</td>
<td>Houston, TX</td>
</tr>
</tbody>
</table>
MEMORANDUM

DATE: May 13, 1970

TO: All Members of the Medical and Research Staffs and Department Heads and Section Chiefs

FROM: Robert C. Hickey, M.D.

SUBJECT: Research Medical Library closed on Monday, May 25, 1970

In anticipation of the opening of the Tenth International Cancer Congress and in conjunction with tours and meetings to be held, the Research Medical Library will be closed all day on Monday, May 25, 1970.

Sincerely,

Robert C. Hickey, M.D.

RCH/rs
<table>
<thead>
<tr>
<th>NAME</th>
<th>INSTITUTE</th>
<th>COUNTRY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prof. Alexandrov</td>
<td>Oncol. Institute</td>
<td>USSR, Minsk, BSSR</td>
</tr>
<tr>
<td>Robert A. Johnson</td>
<td>Univ. of Wisconsin</td>
<td>USA</td>
</tr>
<tr>
<td>Karl G. Schirrmacher</td>
<td>Institute für Klinische Tumorforschung</td>
<td>Germany, Dül - Neuen Essén</td>
</tr>
<tr>
<td>T.R. Allbrook MD, D.C. R.</td>
<td>Philadelphia, Pa</td>
<td>USA</td>
</tr>
<tr>
<td>Koszarowski</td>
<td>Curie Institute of Oncology</td>
<td>Poland</td>
</tr>
<tr>
<td>John Spraitt</td>
<td>Ellis Fischel Cancer Hosp. &amp; Res. Ctr.</td>
<td>USA</td>
</tr>
<tr>
<td>Evar Hecker</td>
<td>German Cancer Res. Center</td>
<td>Germany, Heidelberg</td>
</tr>
<tr>
<td>P.J. Pickett</td>
<td>Children's Med. Res. Faculty</td>
<td>USA</td>
</tr>
<tr>
<td>Alice P. Murphy</td>
<td>Lowell Park</td>
<td>USA</td>
</tr>
<tr>
<td>H. Kanscheet</td>
<td>Univ. Bovin</td>
<td>Germany</td>
</tr>
<tr>
<td>Michael I. Berman MD</td>
<td>Detriot</td>
<td>USA</td>
</tr>
<tr>
<td>Main G. Talalay M.</td>
<td>National Cancer Inst. Bogota</td>
<td>Hungary</td>
</tr>
<tr>
<td>Masay Watanou M.D.</td>
<td>M.D. Anderson Hospital</td>
<td>USA</td>
</tr>
<tr>
<td>John H. C.O.H.</td>
<td>Hong Kong</td>
<td>Queen Elizabeth</td>
</tr>
<tr>
<td>C. M. Kennedy</td>
<td>Oak Ridge Natl. Laboratory</td>
<td>USA</td>
</tr>
<tr>
<td>Harley R. Russell</td>
<td>McQuade Chem. Corp.</td>
<td>USA</td>
</tr>
<tr>
<td>Ott. Van der Heijden</td>
<td>Netherland Cancer Inst. Amsterdam</td>
<td>USA</td>
</tr>
<tr>
<td>Bela Toth</td>
<td>Eppley Inst. Univ. of Nebraska, Omaha, Neb.</td>
<td>USA</td>
</tr>
<tr>
<td>Eduardo Caceres</td>
<td>Instituto Nacional</td>
<td>Peru, Lima</td>
</tr>
<tr>
<td>V. P. Alves</td>
<td>National Cancer Inst.</td>
<td>Peru, Lima</td>
</tr>
<tr>
<td>Michel Vanderpuyte</td>
<td>Regina Institute</td>
<td>Belgium</td>
</tr>
<tr>
<td>PT 1967</td>
<td></td>
<td>USA</td>
</tr>
<tr>
<td>NAME</td>
<td>INSTITUTE</td>
<td>COUNTRY</td>
</tr>
<tr>
<td>----------------</td>
<td>-----------------------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Torun Poppe</td>
<td>Norwegian Radium Hospital, Oslo</td>
<td>Norway</td>
</tr>
<tr>
<td>Costache Octav</td>
<td>Bucharest Oncological Institute, Romania</td>
<td></td>
</tr>
<tr>
<td>Demetri D. Rezis</td>
<td>Cancer Institute of Pireus, Pireus, Greece</td>
<td></td>
</tr>
<tr>
<td>Szegko G.</td>
<td>Filarix Institute of Oncology, USSR</td>
<td></td>
</tr>
<tr>
<td>Robert D. Martin</td>
<td>M.D. Anderson Hospital, Texas</td>
<td></td>
</tr>
<tr>
<td>John Maynard</td>
<td>IARC</td>
<td>Lyon, France</td>
</tr>
<tr>
<td>Toshio Yoshida</td>
<td>Cancer Institute, Tokyo</td>
<td>Japan</td>
</tr>
<tr>
<td>Toruji Ichikawa</td>
<td>The First National Hospital of Tokyo, Japan</td>
<td></td>
</tr>
<tr>
<td>Roger Danook</td>
<td>Montreal Cancer Institute, Montreal, Canada</td>
<td></td>
</tr>
<tr>
<td>Vessis Philemon</td>
<td>M.D. Tumor Institute, Plovdiv, Yugoslavia</td>
<td></td>
</tr>
<tr>
<td>Dr. Zejko Majicic</td>
<td>Tumor Institute, Zagreb, Yugoslavia</td>
<td></td>
</tr>
<tr>
<td>E. Lima Basto</td>
<td>Instituto Portugueses Oncologia, Lisbon, Portugal</td>
<td></td>
</tr>
<tr>
<td>Y. Sheker</td>
<td>Imperial Cancer Research Fund, London</td>
<td></td>
</tr>
<tr>
<td>H. Fein</td>
<td>Switzerland</td>
<td></td>
</tr>
<tr>
<td>J. A. Nieder</td>
<td>Robert Koch Institute, Berlin, GDR</td>
<td></td>
</tr>
<tr>
<td>A. Aboel Naser</td>
<td>Cancer Institute Cairo, Egypt</td>
<td></td>
</tr>
<tr>
<td>Tjiti H. Van der Weijs</td>
<td>Institute National Cancer Research, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Lisag Faller</td>
<td>Children's Cancer Research Foundation, Boston</td>
<td></td>
</tr>
<tr>
<td>Ursuli A. Michail</td>
<td>Rosenwald Pres. Thrombo Institute</td>
<td></td>
</tr>
<tr>
<td>Rost C. Hickey</td>
<td>M.D. Anderson, USA</td>
<td></td>
</tr>
<tr>
<td>Earl B. Bohm</td>
<td>NCI, NIH, USA</td>
<td></td>
</tr>
<tr>
<td>Sherchenkov</td>
<td>C. Kiev, USSR</td>
<td></td>
</tr>
<tr>
<td>N. Blokhin</td>
<td>Moscow, USSR</td>
<td></td>
</tr>
<tr>
<td>D. Mironov</td>
<td>Moscow, USSR</td>
<td></td>
</tr>
<tr>
<td>J. M. McHone</td>
<td>Eppley Cancer Inst., Omaha, NEB</td>
<td></td>
</tr>
<tr>
<td>L. Almkol</td>
<td>Pasteur, Paris</td>
<td></td>
</tr>
<tr>
<td>NAME</td>
<td>INSTITUTE</td>
<td>COUNTRY</td>
</tr>
<tr>
<td>---------------</td>
<td>--------------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Franklin</td>
<td>John Vettering</td>
<td>USA</td>
</tr>
<tr>
<td>Young Madrigal</td>
<td>W. Gonzalez Martinez Hosp.</td>
<td>USA</td>
</tr>
<tr>
<td>Dr. Kumei</td>
<td></td>
<td>U.S.A.</td>
</tr>
<tr>
<td>Isaac Sepa</td>
<td>Regine Blanche Cancer Inst.</td>
<td>Rome, Italy</td>
</tr>
<tr>
<td>Dargent-Malefij</td>
<td>Centre Neurochirurgie</td>
<td>FRANCE</td>
</tr>
<tr>
<td>Raven A1</td>
<td>Institute of Osteology</td>
<td>USSR</td>
</tr>
<tr>
<td>R. Lee Clarke</td>
<td>City Res. Med. Anderson Hosp.</td>
<td>Hayward, USA</td>
</tr>
</tbody>
</table>
Interoffice Memorandum

TO: Dr. Robert C. Hickey
Deputy Director

DATE: March 11, 1970

FROM: Marie Harvin
Research Medical Librarian

SUBJECT:

Dear Dr. Hickey:

Thank you for letting me know in advance of your need to use the Research Medical Library for a meeting at 5:30 p.m. on Monday, May 25, 1970. We shall close the Library to the public for that period of time needed by your group.

If we can assist you in any other way with the meeting, please let me know.

Copies:  Dr. Murray Copeland
Dr. R. Lee Clark
Information Desk
Housekeeping
Mr. Warren Rutherford
Miss Marie Harvin

March 9, 1970

Dr. Robert C. Hickey

Dear Miss Harvin:

It is my wish to reserve the Research Medical Library for a meeting of various cancer institute directors—world wide—which is being sponsored by the American Association of Cancer Institutes in conjunction with the Xth International Cancer Congress. This meeting will be held on May 25, 1970 (Monday), and it will begin at 5:30 p.m. and hopefully we will be finished by 6:30 or 7 p.m.

Please inform me if there are any complications involved with using the library for this meeting.

Sincerely,

Robert C. Hickey, M.D.

RCH/rs
cc: Dr. Murray Copeland
Dr. R. Lee Clark
Information Desk
Housekeeping
Mr. Warren Rutherford
March 9, 1970

Mr. Arthur Kleifgen

Mrs. Barbara Cardone

Dear Mr. Kleifgen:

This will confirm my telephone conversation with Nina this morning regarding a reception to be held on May 25 p.m. at the Anderson-Mayfair. The French Room has been reserved for a reception of various cancer institute directors--world wide--in conjunction with the XIICC. This will begin at approximately 6:30 p.m. on May 25, 1970. The exact time and the approximate number of people attending will be confirmed at a later date.

Arrangements have been made with Nina for the usual type of food service for receptions.

Sincerely,

(Mrs.) Barbara Cardone
Secretary to
Robert C. Hickey, M.D.

BEC/ra
cc: Dr. Murray M. Copeland
     Dr. R. Lee Clark
March 5, 1970

Robert C. Hickey, M.D.,
Executive Vice President and Director
M.D. Anderson Hospital & Tumor Institute
University of Texas
Houston, Texas 77025

Re: American Association of
Cancer Institutes

Dear Bob:

I thank you for the copy of your February 24 letter to
Frank Horsfall (just received) regarding the sending of letters
of invitation to the various cancer institute directors, both US
and foreign nationals for the Houston meeting next May.

Since our meeting in Buffalo last November, I have
kept this matter in mind, but have been able to note only a few
names other than those that are common to most lists. Several
are in reference to Institutes and Academic Departments other
than those concerned primarily with Oncology. Nevertheless,
to assist you, Frank and Ed Mirand I submit the following:

1) ARGENTINA:

Instituto de Oncologia "Angel H. Rojfo"- Universidad de
Argentina. (Prof. Dr. Domingo Musto, Director, 1960.)

2) AUSTRALIA:

a) The Institute of Clinical Pathology and Medi
Research,
P.O. Box 108, Lidcombe, New South Wales. (Dir
Director, 1961). Present Director not known.

b) Cancer Institute, University of Melbourne, 260 William St.,
Melbourne, Australia. (Present Director not known).

c) The Queensland Radium Institute, Brisbane. (Dr. R.G. Bourne,
Senior Radiotherapist.)
3) **BULGARIA:**

Sofia, Bulgaria. Scientific Research Institute on Epidemiology and Microbiology. Petur Sloynev Andonov, M.D., Head, Department of Virology

4) **CHILE:**

a) University of Chile School of Medicine, Department of Oncology. Prof. Carlos Sayago (Recipient in 1966 of a foreign travel fellowship from the Pan American Health Organization.)

b) University of Chile. Institute of Biology, Casilla 2988, Santiago, Chile. (Present Director not known, formerly Prof. Neghne R. Amador, Director).

5) **CZECHOSLOVAKIA:**

a) Bratislava. Research Institute of Oncology, Dr. Villiam Thurno, Director (1966 visitor to the University of California under joint sponsorship of the National Academy of Sciences (USA) and the Academic of Science in Czechoslovakia.)

b) Prague. Dr. Borilov Kell, Head, Department of Chemistry of Proteins, Institute of Organic Chemistry and Biochemistry, Czechoslovak Academy of Sciences, Prague.

6) **INDIA:**

The Tata Memorial Hospital, Parel, Bombay 12, India. (C. Paymaster, Director.)

7) **IRAN:**

Cancer Institute, Kakh Ave. - Koutche. PASHAN, TEHRAN, Iran. (H. Rahmatian, Director)

8) **ITALY:**

Professor Enrico Anglesio, Instituto Di Oncologia, Dell'Ospedale Di S. Giovanni, E Della Citta Di Torino, Torino, Italy

9) **PERU:**

Institute Nacional De Enfermedades Neoplasicas, Avenida Alfonso Ugarte 825, Lima. (Dr. Eduardo Caceres, Director).
10) **POLAND:**

a) Institute of Oncology, Director, Dr. T. Kossarowski (President of the Polish Medical Society, 1966). (An associate, Dr. Krolikiewicz visited a number of institutions in the United States in 1966. (Warsaw)


11) **USSR - LITHUANIA:**

Prof. M.D. Albertas Telichenas, Director of the Institute of Oncology, Vilnius, Bokshto str. 6, U.S.S.R., Lithuanian S.S.R.

12) **JAPAN:**

a) National Sapporo Hospital and Cancer Center of Hokkaido, SAPPORO, Japan. (Dr. Toshitaka Kanemoto, Head, Dept. Gyn.)

b) Cancer Research Institute, Tokyo University. (Dr. T. Yoshida, Director). (Kamio Oota, M.D., Associate) Cancer Institute Hospital. (Toshio Kurokawa, M.D.)

c) Cancer Research Institute, Kanazawa University, 13-1, Takaramachi, KANAZAWA, Japan. (Director ?)

d) Shinogi Research Laboratory, Shinogi & Co., Ltd., Fukushima-ku, OSAKA, Japan. (Director, Dr. Ken'ichi Takeda. Correspondent: T. Minesita.)

I hope we have a good turnout by our Associates from abroad. Please do not hesitate to call upon me for any assistance I can give you in the remaining chores incident to this project.

Cordially,

DAW:cg

cc: R. Lee Clark, M.D.,
M.M. Copeland, M.D.,
F.L. Horsfall, Jr., M.D.,
E.A. Miranda, M.D.
February 24, 1970

Frank L. Horsfall, Jr., M.D.
President, Association of American Cancer Institutes
25 Sloan-Kettering Institute
444 East 68th Street
New York, New York 10021

Dear Doctor Horsfall:

It is timely, I believe, for you to write (as President, Association of American Cancer Institutes) the letter of invitation to the various cancer institute directors, both U.S. and foreign nationals for the Houston meeting.

Our plan is to hold the initial meeting in our new Research Medical Library which is located at the Southeast entrance of the M. D. Anderson Hospital, and the reception at the Anderson-Mayfair, 1600 Holcombe Blvd.--directly across the street from the Anderson Hospital.

We have set aside Monday, May 25, 1970 from 5:30 to 7 p.m.

The Anderson-Mayfair is presently undergoing major remodeling and might not be completed by May. Thus the reason for this mild change in plans, i.e. Anderson-Mayfair totally.

Your list of individuals to be invited on May 25, has been cross-checked with Doctor Copeland's Office, i.e. those who have already registered. I am enclosing a copy of the list with notations identifying same for information purposes. I presume as discussed at the meeting that the reception costs are to be pro-rated to the AACI membership. Wives were not to be invited. A few additional names have been added. These are not numerically large. You may have others.

With kind regards,

Cordially,

Robert C. Hickey, M.D.
Executive Vice President
and Director

RCH/va
Enclosures

cc: Dr. Edwin A. Mirand
Roswell Park Memorial Institute

Dr. David Wood
Cancer Research Institute

bc: Dr. R. Lee Clark
Dr. Murray Copeland.
Dr. P. B. Medawar  
National Institute for Medical Research  
Mill Hill  
London N.W. 7, UNITED KINGDOM

Dr. A. Haddow  
Institute of Cancer Research  
Royal Cancer Hospital  
University of London  
Fulham Road  
London W.W. 3, UNITED KINGDOM

Prof. A. L. Nasr  
Cancer Institute, Faculty of Medicine  
University of Cairo  
Kasr el- Aini Street  
Cairo, U.A.R.

Dr. M. El Kharadly  
Medical Research Institute  
P.O.B. El Madara, Alexandria, UAR

Dr. P. Carda  
Instituto Nacional de Oncología  
Dirección General de Sanidad  
Ciudad Universitaria  
Madrid 3, SPAIN

Dr. O. Costache  
Oncological Institute  
Ministry of Health and Social Welfare  
Blvd. 1 Mai No. 11  
Bucharest, ROMANIA

Dr. A. Oliveras-Guerra  
I Gonzalez Martinez Oncologic Hospital  
Puerto Rico Medical Center  
Box 1811  
Hato Rey, PUERTO RICO

Dr. R. M. Gonzalez  
Hospital de Oncología  
National Medical Center  
Mexican Social Security Institute  
México, D.F.

Dr. C. Zuckermann  
Instituto Nacional de Cancerología  
Avenida Niños Héroes 151  
México 7, D.F.
Dr. T. Yoshida
Cancer Institute
Japanese Foundation for Cancer Research
2615, Nishisugamo 2-chome Toshima-ku
Tokyo, JAPAN

Dr. W. Nakahara
National Cancer Center Research Institute
Ministry of Health and Welfare
Tsukiji 5-chome, Chuo-ku
Tokyo, JAPAN

Dr. Masaru Kuru
National Cancer Center Hospital
Ministry of Health and Welfare
Tsukiji 5-chome, Chuo-ku
Tokyo, JAPAN

Dr. T. Yoshida
Sasaki Institute
Sasaki Foundation
2-2 Surugadai, Kanda, Chiyoda-ku
Tokyo, JAPAN

Dr. T. Ichikawa
The First National Hospital of Tokyo
1, Toyamacho, Shinjuku-ku
Tokyo, JAPAN

Dr. P. Foltz
Institut d'Oncologie
Hôpital San Giovanni
Turin, Italy

Dr. P. Verga
Institut des Tumeurs
Fondation Pascale
Cappella dei Cangiani
Naples, ITALY

Dr. M. Margottini
Institut Regina Elena
Ministere de la Sante
Viale Regina Elena 291
Rome, ITALY

Dr. Oliver Chance
St. Luke's Hospital
Highfield Road
Dublin, IRELAND
Prof. H. Rahaatian
Cancer Institute of Iran
Pahlavi Hospital Cancer Research Dept.
Tehran, IRAN

Dr. J.C. Paymaster
Tata Memorial Hospital
Government of India
Hospital Avenue
Parel, Bombay 12, INDIA

Dr. K.J. Ranadive
Indian Cancer Research Centre
University of Bombay
Tata Memorial Hospital Compound
Hospital Avenue
Parel, Bombay 12, INDIA

Dr. B. Kellner
Research Institute of Oncopathology
Ministry of Health
Rath Gyorgy-Utca 5
Budapest 12, HUNGARY

Dr. J.H.C. Ho
M.D. Institute of Radiology
Queen Mary Hospital
HONG KONG

Dr. Flavio Andrade M.
Instituto de Cancerologia de Guatemala
6a Avenida 6-58 Zona 11
Guatemala City, GUATEMALA

Dr. F. Schmidt
Research Institute for Experimental Oncology
German Academy of Sciences
Alice-Bloch-Strasse 16
Potsdam-Rehbrucke, EAST GERMANY

Dr. E. Hecker
German Centre for Cancer Research
Berliner Strasse 23
D 69 Heidelberg, GERMANY

Prof. Dr. Herwig Hamperl
Pathologisches Institut der Universitat Bonn
53 Bonn-Venusberg, GERMANY

Dr. J. Bernard
Institut de Recherches sur les Maladies
du Sang et les Leucemies
Faculte de Medecine de Paris
Hospital Saint-Louis
2, place du Dr. Fournier
F 75 Paris 10, FRANCE
Dr. M. Dargent
Centre Leon Berard
26, Rue Laennec
F. 69 Lyon 8, France

Dr. E. Saxen
Finnish Cancer Registry
Cancer Society of Finland
Liisankatu 21, Helsinki, FINLAND

Dr. J. Michel
Cancer Research Institute in Collaboration
with the Cancer Clinic
Radiumstationen
Aarhus, DENMARK

Dr. E.H. Betz
Centre anticancereux
Universite de Liege
1, rue des Bonnes Villes
Liege, BELGIUM

Dr. Ruben Pareja F.
Instituto Cancerologia "Cupertino Arteaga"
Casilla Correo No. 274
Sucre-BOLIVIA

Dr. Z. Brada
Cancer Research Institute
Zluty Kopec 7
Brno, Czechoslovakia

Dr. F. Gentil-Martins
Institut central, Hospital A.C. Camargo
Boite Postale 5171
Sao Paulo., S.P. BRAZIL

Dr. A.M. Evans
British Columbia Cancer Institute
2655 Heather St.
Vancouver 9, BRITISH COLUMBIA

Dr. Antonio Pinto Vieira
National Cancer Institute
Praca Cruz Vermelha 23
Rio de Janeiro, Guanabara, BRAZIL

Dr. J. Guelfi
Centre regional de Lutte contre le Cancer
6, rue du Chapitre
F 35 Rennes, FRANCE

Dr. Rene U. Villarreal
Hospital San Jose de Monterrey, S.A.
Apartado Postal No. 2830
Ave. Independencia Pte. No. 3000
Monterrey, N.L., MEXICO
Dr. Luis Delclos
Hospital General de Asturias
Oviedo Asturias, SPAIN

Dr. Manuel N. Fernández
Clínica Fuerta de Hierro
Centro Nacional de Investigación
Médico Quirúrgicas de la Seguridad Social
San Martín de Porres 4
Madrid 20, SPAIN

Dr. N.N. Blokhin
Institute of Experimental & Clinical Oncology
Academy of Medical Sciences
Kashirskoe Shosse 6
Moscow B-409, USSR

Dr. Tamaki Imai (Director)
Cancer Research Institute
Faculty of Medicine, Kyushu University
1276 Katakasu
Fukuoka, JAPAN

Dr. Toshio Kurokawa (President)
Cancer Society of Miyagi Prefecture
7 Kita-7-bancho
Sendai, JAPAN

Dr. Kiyoshi Hiraki
Director of University Hospital
Institute for Cancer Research
Okayama University Medical School
164 Oka, Okayama JAPAN

Dr. M. Kuru (President)
National Cancer Center
Tsukiji 5-chome
Chuo-Ku, Tokyo, JAPAN

Dr. Kunio Oota (President)
The Japanese Association for Cancer Research
c/o Cancer Institute
Nishisugamo, 2-chome
Toshima-ku, Tokyo, JAPAN

Dr. Enrique Barajas-Vallejo (Director)
Instituto Nacional de Cancerología
Av. Niños Heroes, 151
México 7, D.F. MEXICO

Prof. M. Riveros
Instituto del Cáncer del Paraguay
Av. Peru y Juan de Salazar
Asunción, PARAGUAY
Dr. Eduardo Caceres (Director)
Instituto Nacional de Enfermedades Neoplásicas
Avenida Alfonso Ugarte 825
Lima, PERU

Prof. E. Lima Basto (President)
Liga Portuguesa contra o Cancro
Palhava, Lisboa, PORTUGAL

Dr. Ennuyer
Fondation Curie
26, rue d’Ulm
F 75 Paris 5, FRANCE
MEMORANDUM

April 24, 1970

TO: Members of the Association of American Cancer Institutes

FROM: E. A. Mirand, Secretary-Treasurer

Enclosed please find a copy of the resolution introduced in the House by Congressman Cornelius E. Gallagher, calling for firm national commitment to finding a cure and control for cancer within this decade.

Please handle this material as you feel advisable. However, it seems to me that we should be sponsoring Congressman Gallagher's Bill H. Res. 906.
Dear Friend:

We need your help.

On April 9, I introduced a resolution in the House calling for a firm national commitment to finding a cure and control for cancer within this decade.

My bill (H. RES. 906) calls for annual appropriations of no less than $650 Million until the goal is achieved. Moreover, my bill requires that at least $350 Million be expended within the first two years to construct 5 new cancer research institutes in the United States.

My bill has been referred to the House Committee on Interstate and Foreign Commerce, with forty-seven Members of Congress joined as co-sponsors. With your help, I believe we can pass this measure and attain our common goal.

I am well aware of your dedicated and distinguished work in the fight to conquer cancer. You have been a leader in this battle, and for that all Americans must express thanks. Now, I believe that the time has come for the federal government to provide, at least, the same moral and financial commitment to your work as it has for the space program. This is the aim of my resolution.

How can you help? As one who is an expert in the field, your public endorsement of a national cancer cure program would be invaluable. I am writing you, and many of your distinguished colleagues, to request your signature on the enclosed statement, or a similar one of your own writing. When all the replies are received back in my office, they will be released to the press; please be assured that you will receive an advance copy listing the co-signers.

Time is short. I look forward to hearing from you soon and, hopefully, to receiving your signature affixed to the enclosed statement or one of your own authorship. Should you have any questions or comments, please do not hesitate to contact my office.

Thank you very much for your assistance.

Sincerely,

[Signature]

CORNELIUS E. GALLAGHER, M.D.
PROPOSED DRAFT STATEMENT:

WE THE UNDERSIGNED MEMBERS OF THE MEDICAL AND SCIENTIFIC COMMUNITIES EXPRESS OUR STRONG SUPPORT FOR THE RESOLUTION SPONSORED BY CONGRESSMAN CORNELIUS E. GALLAGHER (H.RES. 906) CALLING FOR A FIRM NATIONAL COMMITMENT TO CURE AND CONTROL CANCER WITHIN THIS DECADE.

WE FURTHER EXPRESS OUR CONVICTION THAT WITH THE LEVEL OF FUNDING AND THE MAGNITUDE OF COMMITMENT AUTHORIZED UNDER THE GALLAGHER RESOLUTION, CANCER CAN BE CURED AND CONTROLLED.

WE BELIEVE, ALONG WITH THOSE WHO HAVE JOINED IN SUPPORT OF H. RES. 906, THAT THERE IS NO EXCUSE FOR PERMITTING CANCER TO CONTINUE ITS KILLING PACE WITH THE GREAT RESOURCES AVAILABLE FOR THE FIGHT. IT IS HIGH TIME TO USE THESE RESOURCES AND CONQUER THIS TRAGIC DISEASE.

WE WHO HAVE BEEN WORKING FOR YEARS AGAINST THIS COMMON ENEMY OF MANKIND URG MAK COLLEAGUES AND OUR FELLOW CITIZENS TO ENDORSE H.RES. 906 AND HELP US WIN THIS BATTLE.

(Signature)

PLEASE RETURN AS SOON AS POSSIBLE TO:
Honorable Cornelius E. Gallagher, M.C.
Room 235
Cannon House Office Building
Washington, D.C. 20515
RESOLUTION TO BE SUBMITTED BY
CONGRESSMAN CORNELIUS E. GALLAGHER, 13TH DISTRICT, NEW JERSEY

Whereas cancer takes the lives of more than 300,000 Americans each year; and

Whereas the death rate from cancer is steadily increasing as our population grows; and

Whereas more than 1,000,000 Americans are currently under treatment for this dread disease; and

Whereas it is clearly in the interests of mankind that this disease be cured and controlled; and

Whereas prominent medical authorities have indicated that cancer can be cured and controlled if the necessary funds are made available; and

Whereas current appropriations are inadequate to accomplish this task; and

Whereas it is both necessary and desirable that a national commitment be immediately undertaken to achieve a cure and control for cancer within this decade: It is hereby

RESOLVED, That it is the sense of the House of Representatives that no less than $650,000,000 be appropriated annually over the next 10 fiscal years for the National Cancer Research Program; and,

BE IT FURTHER RESOLVED, That no less than $250,000,000 of this appropriation be utilized to construct 5 new cancer research institutes in the United States during the first two years of the new appropriations.
<table>
<thead>
<tr>
<th>Co-Sponsor</th>
<th>District</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph P. Addabbo, M.C.</td>
<td>D/New York</td>
</tr>
<tr>
<td>Glenn M. Anderson, M.C.</td>
<td>D/California</td>
</tr>
<tr>
<td>George W. Andrews, M.C.</td>
<td>D/Alabama</td>
</tr>
<tr>
<td>Walter S. Baring, M.C.</td>
<td>D/Nevada</td>
</tr>
<tr>
<td>William A. Barrett, M.C.</td>
<td>D/Pennsylvania</td>
</tr>
<tr>
<td>Edward P. Boland, M.C.</td>
<td>D/Massachusetts</td>
</tr>
<tr>
<td>John Brademas, M.C.</td>
<td>D/Indiana</td>
</tr>
<tr>
<td>Frank J. Brasco, M.C.</td>
<td>D/New York</td>
</tr>
<tr>
<td>George E. Brown, M.C.</td>
<td>D/California</td>
</tr>
<tr>
<td>Phillip Burton, M.C.</td>
<td>D/California</td>
</tr>
<tr>
<td>James A. Byrne, M.C.</td>
<td>D/Pennsylvania</td>
</tr>
<tr>
<td>Bill Chappell, Jr., M.C.</td>
<td>D/Florida</td>
</tr>
<tr>
<td>Don H. Clausen, M.C.</td>
<td>R/California</td>
</tr>
<tr>
<td>William Clay, M.C.</td>
<td>D/Missouri</td>
</tr>
<tr>
<td>Emilio Q. Daddario, M.C.</td>
<td>D/Connecticut</td>
</tr>
<tr>
<td>Dominick V. Daniels, M.C.</td>
<td>D/New Jersey</td>
</tr>
<tr>
<td>John D. Dingell, M.C.</td>
<td>D/Michigan</td>
</tr>
<tr>
<td>Leonard Farbstein, M.C.</td>
<td>D/New York</td>
</tr>
<tr>
<td>Donald M. Fraser, M.C.</td>
<td>D/Minnesota</td>
</tr>
<tr>
<td>Samuel N. Friedel, M.C.</td>
<td>D/Maryland</td>
</tr>
<tr>
<td>Richard Fulton, M.C.</td>
<td>D/Tennessee</td>
</tr>
<tr>
<td>Tom S. Gettys, M.C.</td>
<td>D/South Carolina</td>
</tr>
<tr>
<td>Robert N. Giaimo, M.C.</td>
<td>D/Connecticut</td>
</tr>
<tr>
<td>Kenneth J. Gray, M.C.</td>
<td>D/Illinois</td>
</tr>
<tr>
<td>Seymour Halpern, M.C.</td>
<td>R/New York</td>
</tr>
</tbody>
</table>
James Harvey, M.C.   R/Michigan
William D. Hathaway, M.C.   D/Maine
Henry Helstoski, M.C.   D/New Jersey
Floyd V. Hicks, M.C.   D/Washington
James J. Howard, M.C.   D/New Jersey
Andrew Jacobs, Jr., M.C.   D/Indiana
Allard K. Lowenstein, M.C.   D/New York
Donald E. Lukens, M.C.   R/Ohio
Paul N. McCloskey, Jr., M.C.   R/California
Martin D. McKneally, M.C.   R/New York
Abner J. Mikva, M.C.   D/Illinois
Joseph G. Minish, M.C.   D/New Jersey
John M. Murphy, M.C.   L/New York
Richard L. Ottinger, M.C.   D/New York
Claude Pepper, M.C.   D/Florida
Bertram L. Podell, M.C.   D/New York
Richardson Preyer, M.C.   D/North Carolina
Thomas M. Rees, M.C.   D/California
Robert A. Roe, M.C.   D/New Jersey
William F. Ryan, M.C.   D/New York
Charles W. Sandman, Jr., M.C.   R/New Jersey
Louis Stokes, M.C.   D/Ohio